{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:20:31Z","timestamp":1794007231841,"version":"4.8.0"},"reference-count":245,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T00:00:00Z","timestamp":1550188800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00018-019-03040-5","type":"journal-article","created":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T16:16:39Z","timestamp":1550247399000},"page":"1833-1863","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":99,"title":["Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer\u2019s disease pathogenesis"],"prefix":"10.1007","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6462-7281","authenticated-orcid":false,"given":"Kunal","family":"Dhiman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph N.","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veer Bala","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,15]]},"reference":[{"issue":"3","key":"3040_CR1","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X","volume":"45","author":"JL Price","year":"1999","unstructured":"Price JL, Morris JC (1999) Tangles and plaques in nondemented aging and \u201cpreclinical\u201d Alzheimer\u2019s disease. Ann Neurol 45(3):358\u2013368","journal-title":"Ann Neurol"},{"issue":"3","key":"3040_CR2","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s Dement 7(3):280\u2013292. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.003","journal-title":"Alzheimer\u2019s Dement"},{"issue":"12","key":"3040_CR3","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1073\/pnas.82.12.4245","volume":"82","author":"CL Masters","year":"1985","unstructured":"Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 82(12):4245\u20134249","journal-title":"Proc Natl Acad Sci USA"},{"key":"3040_CR4","doi-asserted-by":"publisher","first-page":"15056","DOI":"10.1038\/nrdp.2015.56","volume":"1","author":"CL Masters","year":"2015","unstructured":"Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL (2015) Alzheimer\u2019s disease. Nat Rev Dis Prim 1:15056. https:\/\/doi.org\/10.1038\/nrdp.2015.56","journal-title":"Nat Rev Dis Prim"},{"issue":"4","key":"3040_CR5","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N Engl J Med 370(4):322\u2013333. https:\/\/doi.org\/10.1056\/NEJMoa1304839","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"3040_CR6","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.neurobiolaging.2011.09.005","volume":"32","author":"JC Morris","year":"2011","unstructured":"Morris JC, Selkoe DJ (2011) Recommendations for the incorporation of biomarkers into Alzheimer clinical trials: an overview. Neurobiol Aging 32(suppl 1):S1\u2013S3. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2011.09.005","journal-title":"Neurobiol Aging"},{"key":"3040_CR7","doi-asserted-by":"publisher","unstructured":"Sperling RA, Jack CR, Aisen PS (2011) Testing the right target and the right drug at the right stage. Sci Transl Med 3 (111):111\u2013133. https:\/\/doi.org\/10.1126\/scitranslmed.3002609","DOI":"10.1126\/scitranslmed.3002609"},{"issue":"11","key":"3040_CR8","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1038\/nm.2221","volume":"16","author":"K Blennow","year":"2010","unstructured":"Blennow K (2010) Biomarkers in Alzheimer\u2019s disease drug development. Nat Med 16(11):1218\u20131222","journal-title":"Nat Med"},{"issue":"1","key":"3040_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3233\/jad-160573","volume":"55","author":"SP Arneric","year":"2016","unstructured":"Arneric SP, Batrla-Utermann R, Beckett L, Bittner T, Blennow K, Carter L, Dean R, Engelborghs S, Genius J, Gordon MF, Hitchcock J, Kaplow J, Luthman J, Meibach R, Raunig D, Romero K, Samtani MN, Savage M, Shaw L, Stephenson D, Umek RM, Vanderstichele H, Willis B, Yule S (2016) Cerebrospinal fluid biomarkers for Alzheimer\u2019s disease: a view of the regulatory science qualification landscape from the coalition against major diseases CSF biomarker team. J Alzheimer\u2019s Dis 55(1):19\u201335. https:\/\/doi.org\/10.3233\/jad-160573","journal-title":"J Alzheimer\u2019s Dis"},{"key":"3040_CR10","first-page":"47","volume":"6","author":"D Ferreira","year":"2014","unstructured":"Ferreira D, Perestelo-P\u00e9rez L, Westman E, Wahlund L-O, Sarr\u00eda A, Serrano-Aguilar P (2014) Meta-review of CSF core biomarkers in Alzheimer\u2019s disease: the state-of-the-art after the new revised diagnostic criteria. Front Aging Neurosci 6:47","journal-title":"Front Aging Neurosci"},{"issue":"5","key":"3040_CR11","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1212\/wnl.0000000000002923","volume":"87","author":"CR Jack","year":"2016","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, Hampel H, Jagust WJ, Johnson KA, Knopman DS, Petersen RC, Scheltens P, Sperling RA, Dubois B (2016) A\/T\/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87(5):539\u2013547. https:\/\/doi.org\/10.1212\/wnl.0000000000002923","journal-title":"Neurology"},{"issue":"7","key":"3040_CR12","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nrd3115","volume":"9","author":"H Hampel","year":"2010","unstructured":"Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, Herholz K, Bokde ALW, Jessen F, Hoessler YC, Sanhai WR, Zetterberg H, Woodcock J, Blennow K (2010) Biomarkers for Alzheimer\u2019s disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 9(7):560\u2013574","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"3040_CR13","doi-asserted-by":"publisher","first-page":"a006213","DOI":"10.1101\/cshperspect.a006213","volume":"2","author":"KA Johnson","year":"2012","unstructured":"Johnson KA, Fox NC, Sperling RA, Klunk WE (2012) Brain imaging in Alzheimer disease. Cold Spring Harbor Perspect Med 2(4):a006213","journal-title":"Cold Spring Harbor Perspect Med"},{"key":"3040_CR14","unstructured":"Fishman RA (1992) Cerebrospinal fluid in diseases of the nervous system. WB Saunders Company, Philadelphia"},{"key":"3040_CR15","doi-asserted-by":"publisher","unstructured":"Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer\u2019s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. https:\/\/doi.org\/10.1016\/s1474-4422(06)70355-6","DOI":"10.1016\/s1474-4422(06)70355-6"},{"issue":"7","key":"3040_CR16","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2217\/bmm-2017-0433","volume":"12","author":"NJ Ashton","year":"2018","unstructured":"Ashton NJ, Scholl M, Heurling K, Gkanatsiou E, Portelius E, Hoglund K, Brinkmalm G, Hye A, Blennow K, Zetterberg H (2018) Update on biomarkers for amyloid pathology in Alzheimer\u2019s disease. Biomark Med 12(7):799\u2013812. https:\/\/doi.org\/10.2217\/bmm-2017-0433","journal-title":"Biomark Med"},{"issue":"4","key":"3040_CR17","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.neuron.2018.04.035","volume":"98","author":"C Sato","year":"2018","unstructured":"Sato C, Barthelemy NR, Mawuenyega KG, Patterson BW, Gordon BA, Jockel-Balsarotti J, Sullivan M, Crisp MJ, Kasten T, Kirmess KM, Kanaan NM, Yarasheski KE, Baker-Nigh A, Benzinger TLS, Miller TM, Karch CM, Bateman RJ (2018) Tau kinetics in neurons and the human central nervous system. Neuron 98(4):861\u2013864. https:\/\/doi.org\/10.1016\/j.neuron.2018.04.035","journal-title":"Neuron"},{"issue":"6","key":"3040_CR18","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R (2014) Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. Lancet Neurol 13(6):614\u2013629","journal-title":"Lancet Neurol"},{"issue":"3","key":"3040_CR19","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jalz.2011.03.004","volume":"7","author":"CR Jack","year":"2011","unstructured":"Jack CR, Albert M, Knopman DS, McKhann GM, Sperling RA, Carillo M, Thies W, Phelps CH (2011) Introduction to revised criteria for the diagnosis of Alzheimer\u2019s disease: National Institute on Aging and the Alzheimer Association Workgroups. Alzheimer\u2019s Dement 7(3):257\u2013262. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.004","journal-title":"Alzheimer\u2019s Dement"},{"issue":"3","key":"3040_CR20","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/bf02815140","volume":"26","author":"K Blennow","year":"1995","unstructured":"Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E (1995) Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 26(3):231\u2013245. https:\/\/doi.org\/10.1007\/bf02815140","journal-title":"Mol Chem Neuropathol"},{"issue":"4","key":"3040_CR21","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/ana.410380413","volume":"38","author":"R Motter","year":"1995","unstructured":"Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, Chang L, Miller B, Clark C, Green R et al (1995) Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer\u2019s disease. Ann Neurol 38(4):643\u2013648. https:\/\/doi.org\/10.1002\/ana.410380413","journal-title":"Ann Neurol"},{"issue":"10","key":"3040_CR22","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S1474-4422(03)00530-1","volume":"2","author":"K Blennow","year":"2003","unstructured":"Blennow K, Hampel H (2003) CSF markers for incipient Alzheimer\u2019s disease. Lancet Neurol 2(10):605\u2013613","journal-title":"Lancet Neurol"},{"issue":"7266","key":"3040_CR23","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/nature08538","volume":"461","author":"RJ Perrin","year":"2009","unstructured":"Perrin RJ, Fagan AM, Holtzman DM (2009) Multimodal techniques for diagnosis and prognosis of Alzheimer\u2019s disease. Nature 461(7266):916\u2013922. https:\/\/doi.org\/10.1038\/nature08538","journal-title":"Nature"},{"issue":"1","key":"3040_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3233\/jad-2009-1124","volume":"18","author":"B Zhou","year":"2009","unstructured":"Zhou B, Teramukai S, Yoshimura K, Fukushima M (2009) Validity of cerebrospinal fluid biomarkers as endpoints in early-phase clinical trials for Alzheimer\u2019s disease. J Alzheimer\u2019s Dis 18(1):89\u2013102. https:\/\/doi.org\/10.3233\/jad-2009-1124","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"1","key":"3040_CR25","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/s1474-4422(09)70299-6","volume":"9","author":"CR Jack Jr","year":"2010","unstructured":"Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade. Lancet Neurol 9(1):119\u2013128. https:\/\/doi.org\/10.1016\/s1474-4422(09)70299-6","journal-title":"Lancet Neurol"},{"issue":"17","key":"3040_CR26","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1212\/WNL.0b013e3181bd8271","volume":"73","author":"MI Kester","year":"2009","unstructured":"Kester MI, van der Vlies AE, Blankenstein MA, Pijnenburg YA, van Elk EJ, Scheltens P, van der Flier WM (2009) CSF biomarkers predict rate of cognitive decline in Alzheimer disease. Neurology 73(17):1353\u20131358. https:\/\/doi.org\/10.1212\/WNL.0b013e3181bd8271","journal-title":"Neurology"},{"issue":"5","key":"3040_CR27","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00401-013-1151-4","volume":"126","author":"JB Toledo","year":"2013","unstructured":"Toledo JB, Xie SX, Trojanowski JQ, Shaw LM (2013) Longitudinal change in CSF Tau and Abeta biomarkers for up to 48\u00a0months in ADNI. Acta Neuropathol 126(5):659\u2013670. https:\/\/doi.org\/10.1007\/s00401-013-1151-4","journal-title":"Acta Neuropathol"},{"issue":"9","key":"3040_CR28","doi-asserted-by":"publisher","first-page":"a006221","DOI":"10.1101\/cshperspect.a006221","volume":"2","author":"K Blennow","year":"2012","unstructured":"Blennow K, Zetterberg H, Fagan AM (2012) Fluid biomarkers in Alzheimer disease. Cold Spring Harb Perspect Med 2(9):a006221. https:\/\/doi.org\/10.1101\/cshperspect.a006221","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"9634","key":"3040_CR29","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/s0140-6736(08)61075-2","volume":"372","author":"C Holmes","year":"2008","unstructured":"Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA (2008) Long-term effects of Abeta42 immunisation in Alzheimer\u2019s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet (London, England) 372(9634):216\u2013223. https:\/\/doi.org\/10.1016\/s0140-6736(08)61075-2","journal-title":"Lancet (London, England)"},{"issue":"5","key":"3040_CR30","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.tips.2015.03.002","volume":"36","author":"K Blennow","year":"2015","unstructured":"Blennow K, Mattsson N, Sch\u00f6ll M, Hansson O, Zetterberg H (2015) Amyloid biomarkers in Alzheimer\u2019s disease. Trends Pharmacol Sci 36(5):297\u2013309. https:\/\/doi.org\/10.1016\/j.tips.2015.03.002","journal-title":"Trends Pharmacol Sci"},{"issue":"Pt 3","key":"3040_CR31","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/brain\/awu367","volume":"138","author":"N Mattsson","year":"2015","unstructured":"Mattsson N, Insel PS, Donohue M, Landau S, Jagust WJ, Shaw LM, Trojanowski JQ, Zetterberg H, Blennow K, Weiner MW (2015) Independent information from cerebrospinal fluid amyloid-beta and florbetapir imaging in Alzheimer\u2019s disease. Brain 138(Pt 3):772\u2013783. https:\/\/doi.org\/10.1093\/brain\/awu367","journal-title":"Brain"},{"issue":"Pt 4","key":"3040_CR32","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1093\/brain\/aww015","volume":"139","author":"S Palmqvist","year":"2016","unstructured":"Palmqvist S, Mattsson N, Hansson O (2016) Cerebrospinal fluid analysis detects cerebral amyloid-beta accumulation earlier than positron emission tomography. Brain 139(Pt 4):1226\u20131236. https:\/\/doi.org\/10.1093\/brain\/aww015","journal-title":"Brain"},{"issue":"3","key":"3040_CR33","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ana.20730","volume":"59","author":"AM Fagan","year":"2006","unstructured":"Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59(3):512\u2013519. https:\/\/doi.org\/10.1002\/ana.20730","journal-title":"Ann Neurol"},{"issue":"4","key":"3040_CR34","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3233\/jad-142952","volume":"45","author":"A Leuzy","year":"2015","unstructured":"Leuzy A, Carter SF, Chiotis K, Almkvist O, Wall A, Nordberg A (2015) Concordance and diagnostic accuracy of [11C]PIB PET and cerebrospinal fluid biomarkers in a sample of patients with mild cognitive impairment and Alzheimer\u2019s disease. J Alzheimer\u2019s Dis 45(4):1077\u20131088. https:\/\/doi.org\/10.3233\/jad-142952","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"1","key":"3040_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2050-7771-1-1","volume":"1","author":"C-T Hsueh","year":"2013","unstructured":"Hsueh C-T, Liu D, Wang H (2013) Novel biomarkers for diagnosis, prognosis, targeted therapy and clinical trials. Biomark Res 1(1):1","journal-title":"Biomark Res"},{"key":"3040_CR36","unstructured":"Counts SE, Ikonomovic MD, Mercado N, Vega IE, Mufson EJ (2016) Biomarkers for the early detection and progression of Alzheimer\u2019s disease. Neurotherapeutics 1\u201319"},{"issue":"4","key":"3040_CR37","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2217\/bmm.12.42","volume":"6","author":"AM Fagan","year":"2012","unstructured":"Fagan AM, Perrin RJ (2012) Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer\u2019s disease. Biomark Med 6(4):455\u2013476. https:\/\/doi.org\/10.2217\/bmm.12.42","journal-title":"Biomark Med"},{"issue":"4852","key":"3040_CR38","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1126\/science.3283935","volume":"240","author":"RW Mahley","year":"1988","unstructured":"Mahley RW (1988) Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science (New York, NY) 240(4852):622\u2013630","journal-title":"Science (New York, NY)"},{"issue":"1","key":"3040_CR39","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/0005-2760(87)90295-5","volume":"917","author":"RE Pitas","year":"1987","unstructured":"Pitas RE, Boyles JK, Lee SH, Foss D, Mahley RW (1987) Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochem Biophys Acta 917(1):148\u2013161","journal-title":"Biochem Biophys Acta"},{"issue":"2","key":"3040_CR40","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1006\/exnr.1996.6360","volume":"143","author":"DJ Stone","year":"1997","unstructured":"Stone DJ, Rozovsky I, Morgan TE, Anderson CP, Hajian H, Finch CE (1997) Astrocytes and microglia respond to estrogen with increased apoE mRNA in vivo and in vitro. Exp Neurol 143(2):313\u2013318. https:\/\/doi.org\/10.1006\/exnr.1996.6360","journal-title":"Exp Neurol"},{"issue":"5\u20136","key":"3040_CR41","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S0197-0186(01)00049-3","volume":"39","author":"RB DeMattos","year":"2001","unstructured":"DeMattos RB, Brendza RP, Heuser JE, Kierson M, Cirrito JR, Fryer J, Sullivan PM, Fagan AM, Han X, Holtzman DM (2001) Purification and characterization of astrocyte-secreted apolipoprotein E and J-containing lipoproteins from wild-type and human apoE transgenic mice. Neurochem Int 39(5\u20136):415\u2013425. https:\/\/doi.org\/10.1016\/S0197-0186(01)00049-3","journal-title":"Neurochem Int"},{"issue":"10","key":"3040_CR42","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.molmed.2010.07.008","volume":"16","author":"V Leduc","year":"2010","unstructured":"Leduc V, Jasmin-Belanger S, Poirier J (2010) APOE and cholesterol homeostasis in Alzheimer\u2019s disease. Trends Mol Med 16(10):469\u2013477. https:\/\/doi.org\/10.1016\/j.molmed.2010.07.008","journal-title":"Trends Mol Med"},{"issue":"5","key":"3040_CR43","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.ajhg.2008.10.008","volume":"83","author":"L Bertram","year":"2008","unstructured":"Bertram L, Lange C, Mullin K, Parkinson M, Hsiao M, Hogan MF, Schjeide BMM, Hooli B, DiVito J, Ionita I, Jiang H, Laird N, Moscarillo T, Ohlsen KL, Elliott K, Wang X, Hu-Lince D, Ryder M, Murphy A, Wagner SL, Blacker D, Becker KD, Tanzi RE (2008) Genome-wide association analysis reveals putative Alzheimer\u2019s disease susceptibility loci in addition to APOE. Am J Hum Genet 83(5):623\u2013632. https:\/\/doi.org\/10.1016\/j.ajhg.2008.10.008","journal-title":"Am J Hum Genet"},{"issue":"4","key":"3040_CR44","doi-asserted-by":"publisher","first-page":"613","DOI":"10.4088\/JCP.v68n0419","volume":"68","author":"KD Coon","year":"2007","unstructured":"Coon KD, Myers AJ, Craig DW, Webster JA, Pearson JV, Lince DH, Zismann VL, Beach TG, Leung D, Bryden L, Halperin RF, Marlowe L, Kaleem M, Walker DG, Ravid R, Heward CB, Rogers J, Papassotiropoulos A, Reiman EM, Hardy J, Stephan DA (2007) A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer\u2019s disease. J Clin Psychiatry 68(4):613\u2013618","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"3040_CR45","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/0169-328X(91)90111-A","volume":"11","author":"J Poirier","year":"1991","unstructured":"Poirier J, Hess M, May PC, Finch CE (1991) Astrocytic apolipoprotein E mRNA and GFAP mRNA in hippocampus after entorhinal cortex lesioning. Brain Res Mol Brain Res 11(2):97\u2013106","journal-title":"Brain Res Mol Brain Res"},{"issue":"33","key":"3040_CR46","doi-asserted-by":"publisher","first-page":"29919","DOI":"10.1074\/jbc.M203934200","volume":"277","author":"JS Gong","year":"2002","unstructured":"Gong JS, Kobayashi M, Hayashi H, Zou K, Sawamura N, Fujita SC, Yanagisawa K, Michikawa M (2002) Apolipoprotein E (ApoE) isoform-dependent lipid release from astrocytes prepared from human ApoE3 and ApoE4 knock-in mice. J Biol Chem 277(33):29919\u201329926. https:\/\/doi.org\/10.1074\/jbc.M203934200","journal-title":"J Biol Chem"},{"issue":"3","key":"3040_CR47","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1046\/j.1471-4159.2000.0741008.x","volume":"74","author":"M Michikawa","year":"2000","unstructured":"Michikawa M, Fan QW, Isobe I, Yanagisawa K (2000) Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture. J Neurochem 74(3):1008\u20131016","journal-title":"J Neurochem"},{"issue":"Pt 2","key":"3040_CR48","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1042\/bj3480359","volume":"348","author":"T Tokuda","year":"2000","unstructured":"Tokuda T, Calero M, Matsubara E, Vidal R, Kumar A, Permanne B, Zlokovic B, Smith JD, Ladu MJ, Rostagno A, Frangione B, Ghiso J (2000) Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer\u2019s amyloid beta peptides. Biochem J 348(Pt 2):359\u2013365","journal-title":"Biochem J"},{"issue":"5","key":"3040_CR49","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nrn2620","volume":"10","author":"G Bu","year":"2009","unstructured":"Bu G (2009) Apolipoprotein E and its receptors in Alzheimer\u2019s disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 10(5):333\u2013344","journal-title":"Nat Rev Neurosci"},{"issue":"3","key":"3040_CR50","doi-asserted-by":"publisher","first-page":"a006312","DOI":"10.1101\/cshperspect.a006312","volume":"2","author":"DM Holtzman","year":"2012","unstructured":"Holtzman DM, Herz J, Bu G (2012) Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harbor Perspect Med 2(3):a006312. https:\/\/doi.org\/10.1101\/cshperspect.a006312","journal-title":"Cold Spring Harbor Perspect Med"},{"issue":"5","key":"3040_CR51","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.neuron.2008.04.010","volume":"58","author":"Q Jiang","year":"2008","unstructured":"Jiang Q, Lee CD, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL (2008) ApoE promotes the proteolytic degradation of A\u03b2. Neuron 58(5):681\u2013693","journal-title":"Neuron"},{"key":"3040_CR52","doi-asserted-by":"crossref","unstructured":"Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, Holtzman DM, Zlokovic BV (2008) apoE isoform-specific disruption of amyloid \u03b2 peptide clearance from mouse brain. J Clin Invest 118(12):4002-4013","DOI":"10.1172\/JCI36663"},{"key":"3040_CR53","first-page":"225532","volume":"M111","author":"K Nishitsuji","year":"2011","unstructured":"Nishitsuji K, Hosono T, Nakamura T, Bu G, Michikawa M (2011) Apolipoprotein E regulates the integrity of tight junctions in an isoform-dependent manner in an in vitro blood\u2013brain-barrier model. J Biol Chem M111:225532","journal-title":"J Biol Chem"},{"issue":"6501","key":"3040_CR54","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/372092a0","volume":"372","author":"J Ma","year":"1994","unstructured":"Ma J, Yee A, Brewer HB Jr, Das S, Potter H (1994) Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 372(6501):92\u201394. https:\/\/doi.org\/10.1038\/372092a0","journal-title":"Nature"},{"issue":"26","key":"3040_CR55","doi-asserted-by":"publisher","first-page":"15233","DOI":"10.1073\/pnas.96.26.15233","volume":"96","author":"KR Bales","year":"1999","unstructured":"Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, Saura J, Fishman CE, DeLong CA, Piccardo P, Petegnief V, Ghetti B, Paul SM (1999) Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer\u2019s disease. Proc Natl Acad Sci 96(26):15233\u201315238. https:\/\/doi.org\/10.1073\/pnas.96.26.15233","journal-title":"Proc Natl Acad Sci"},{"key":"3040_CR56","doi-asserted-by":"publisher","unstructured":"Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, Goate AM, Bales KR, Paul SM, Bateman RJ, Holtzman DM (2011) Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci Transl Med 3(89):89ra57. https:\/\/doi.org\/10.1126\/scitranslmed.3002156","DOI":"10.1126\/scitranslmed.3002156"},{"issue":"7673","key":"3040_CR57","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nature24016","volume":"549","author":"Y Shi","year":"2017","unstructured":"Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, Tsai RM, Spina S, Grinberg LT, Rojas JC, Gallardo G, Wang K, Roh J, Robinson G, Finn MB, Jiang H, Sullivan PM, Baufeld C, Wood MW, Sutphen C, McCue L, Xiong C, Del-Aguila JL, Morris JC, Cruchaga C, Fagan AM, Miller BL, Boxer AL, Seeley WW, Butovsky O, Barres BA, Paul SM, Holtzman DM (2017) ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549(7673):523\u2013527. https:\/\/doi.org\/10.1038\/nature24016","journal-title":"Nature"},{"issue":"3","key":"3040_CR58","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/s0002-9440(10)64963-2","volume":"156","author":"I Tesseur","year":"2000","unstructured":"Tesseur I, Van Dorpe J, Spittaels K, Van den Haute C, Moechars D, Van Leuven F (2000) Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice. Am J Pathol 156(3):951\u2013964. https:\/\/doi.org\/10.1016\/s0002-9440(10)64963-2","journal-title":"Am J Pathol"},{"key":"3040_CR59","doi-asserted-by":"publisher","unstructured":"Shi Y, Holtzman DM (2018) Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Nat Rev Immunol. https:\/\/doi.org\/10.1038\/s41577-018-0051-1","DOI":"10.1038\/s41577-018-0051-1"},{"issue":"9","key":"3040_CR60","doi-asserted-by":"publisher","first-page":"4646","DOI":"10.1073\/pnas.76.9.4646","volume":"76","author":"PS Roheim","year":"1979","unstructured":"Roheim PS, Carey M, Forte T, Vega GL (1979) Apolipoproteins in human cerebrospinal fluid. Proc Natl Acad Sci 76(9):4646\u20134649","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"3040_CR61","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1309\/w01y0b808emeh12l","volume":"129","author":"J Zhang","year":"2008","unstructured":"Zhang J, Sokal I, Peskind ER, Quinn JF, Jankovic J, Kenney C, Chung KA, Millard SP, Nutt JG, Montine TJ (2008) CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol 129(4):526\u2013529. https:\/\/doi.org\/10.1309\/w01y0b808emeh12l","journal-title":"Am J Clin Pathol"},{"issue":"18","key":"3040_CR62","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1097\/00001756-199412000-00032","volume":"5","author":"K Blennow","year":"1994","unstructured":"Blennow K, Hesse C, Fredman P (1994) Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer\u2019s disease. NeuroReport 5(18):2534\u20132536","journal-title":"NeuroReport"},{"issue":"5","key":"3040_CR63","first-page":"273","volume":"7","author":"M Landen","year":"1996","unstructured":"Landen M, Hesse C, Fredman P, Regland B, Wallin A, Blennow K (1996) Apolipoprotein E in cerebrospinal fluid from patients with Alzheimer\u2019s disease and other forms of dementia is reduced but without any correlation to the apoE4 isoform. Dementia (Basel, Switzerland) 7(5):273\u2013278","journal-title":"Dementia (Basel, Switzerland)"},{"issue":"1","key":"3040_CR64","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0304-3940(98)00381-4","volume":"249","author":"T Pirttil\u00e4","year":"1998","unstructured":"Pirttil\u00e4 T, Koivisto K, Mehta PD, Reinikainen K, Kim KS, Kilkku O, Heinonen E, Soininen H, Riekkinen P Sr, Wisniewski HM (1998) Longitudinal study of cerebrospinal fluid amyloid proteins and apolipoprotein E in patients with probable Alzheimer\u2019s disease. Neurosci Lett 249(1):21\u201324","journal-title":"Neurosci Lett"},{"issue":"2","key":"3040_CR65","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0304-3940(97)00429-1","volume":"229","author":"M Lindh","year":"1997","unstructured":"Lindh M, Blomberg M, Jensen M, Basun H, Lannfelt L, Engvall B, Scharnagel H, Marz W, Wahlund LO, Cowburn RF (1997) Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer\u2019s disease patients are increased at follow up and show a correlation with levels of tau protein. Neurosci Lett 229(2):85\u201388","journal-title":"Neurosci Lett"},{"issue":"3","key":"3040_CR66","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1159\/000008157","volume":"43","author":"R Fukuyama","year":"2000","unstructured":"Fukuyama R, Mizuno T, Mori S, Yanagisawa K, Nakajima K, Fushiki S (2000) Age-dependent decline in the apolipoprotein E level in cerebrospinal fluid from control subjects and its increase in cerebrospinal fluid from patients with Alzheimer\u2019s disease. Eur Neurol 43(3):161\u2013169","journal-title":"Eur Neurol"},{"issue":"1","key":"3040_CR67","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0022-510X(96)00234-1","volume":"145","author":"A Merched","year":"1997","unstructured":"Merched A, Blain H, Visvikis S, Herbeth B, Jeandel C, Siest G (1997) Cerebrospinal fluid apolipoprotein E level is increased in late-onset Alzheimer\u2019s disease. J Neurol Sci 145(1):33\u201339","journal-title":"J Neurol Sci"},{"issue":"4","key":"3040_CR68","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1023\/A:1007516210548","volume":"25","author":"C Hesse","year":"2000","unstructured":"Hesse C, Larsson H, Fredman P, Minthon L, Andreasen N, Davidsson P, Blennow K (2000) Measurement of apolipoprotein E (apoE) in cerebrospinal fluid. Neurochem Res 25(4):511\u2013517","journal-title":"Neurochem Res"},{"issue":"5","key":"3040_CR69","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00401-014-1266-2","volume":"127","author":"E Martinez-Morillo","year":"2014","unstructured":"Martinez-Morillo E, Hansson O, Atagi Y, Bu G, Minthon L, Diamandis EP, Nielsen HM (2014) Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer\u2019s disease patients and controls. Acta Neuropathol 127(5):633\u2013643. https:\/\/doi.org\/10.1007\/s00401-014-1266-2","journal-title":"Acta Neuropathol"},{"issue":"23","key":"3040_CR70","doi-asserted-by":"publisher","first-page":"11183","DOI":"10.1073\/pnas.91.23.11183","volume":"91","author":"WJ Strittmatter","year":"1994","unstructured":"Strittmatter WJ, Saunders AM, Goedert M, Weisgraber KH, Dong L-M, Jakes R, Huang DY, Pericak-Vance M, Schmechel D, Roses AD (1994) Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc Natl Acad Sci 91(23):11183\u201311186","journal-title":"Proc Natl Acad Sci"},{"key":"3040_CR71","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.neurobiolaging.2017.04.002","volume":"57","author":"AC Harten van","year":"2017","unstructured":"van Harten AC, Jongbloed W, Teunissen CE, Scheltens P, Veerhuis R, van der Flier WM (2017) CSF ApoE predicts clinical progression in nondemented APOE\u03b54 carriers. Neurobiol Aging 57:186\u2013194. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2017.04.002","journal-title":"Neurobiol Aging"},{"issue":"3","key":"3040_CR72","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.3233\/jad-170226","volume":"59","author":"P Johansson","year":"2017","unstructured":"Johansson P, Almqvist EG, Bjerke M, Wallin A, Johansson JO, Andreasson U, Blennow K, Zetterberg H, Svensson J (2017) Reduced cerebrospinal fluid concentration of apolipoprotein A-I in patients with Alzheimer\u2019s disease. J Alzheimer\u2019s Dis 59(3):1017\u20131026. https:\/\/doi.org\/10.3233\/jad-170226","journal-title":"J Alzheimer\u2019s Dis"},{"key":"3040_CR73","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.euprot.2015.07.012","volume":"8","author":"M Rezeli","year":"2015","unstructured":"Rezeli M, Zetterberg H, Blennow K, Brinkmalm A, Laurell T, Hansson O, Marko-Varga G (2015) Quantification of total apolipoprotein E and its specific isoforms in cerebrospinal fluid and blood in Alzheimer\u2019s disease and other neurodegenerative diseases. EuPA Open Proteomics 8:137\u2013143. https:\/\/doi.org\/10.1016\/j.euprot.2015.07.012","journal-title":"EuPA Open Proteomics"},{"issue":"2","key":"3040_CR74","first-page":"53","volume":"5","author":"JL Richens","year":"2014","unstructured":"Richens JL, Vere KA, Light RA, Soria D, Garibaldi J, Smith AD, Warden D, Wilcock G, Bajaj N, Morgan K, O\u2019Shea P (2014) Practical detection of a definitive biomarker panel for Alzheimer\u2019s disease; comparisons between matched plasma and cerebrospinal fluid. Int J Mol Epidemiol Genet 5(2):53\u201370","journal-title":"Int J Mol Epidemiol Genet"},{"issue":"5","key":"3040_CR75","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00401-013-1236-0","volume":"127","author":"JB Toledo","year":"2014","unstructured":"Toledo JB, Da X, Weiner MW, Wolk DA, Xie SX, Arnold SE, Davatzikos C, Shaw LM, Trojanowski JQ (2014) CSF Apo-E levels associate with cognitive decline and MRI changes. Acta Neuropathol 127(5):621\u2013632. https:\/\/doi.org\/10.1007\/s00401-013-1236-0","journal-title":"Acta Neuropathol"},{"issue":"1","key":"3040_CR76","doi-asserted-by":"publisher","first-page":"e16032","DOI":"10.1371\/journal.pone.0016032","volume":"6","author":"RJ Perrin","year":"2011","unstructured":"Perrin RJ, Craig-Schapiro R, Malone JP, Shah AR, Gilmore P, Davis AE, Roe CM, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, Kaye JA, Morris JC, Holtzman DM, Townsend RR, Fagan AM (2011) Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer\u2019s disease. PLoS ONE 6(1):e16032. https:\/\/doi.org\/10.1371\/journal.pone.0016032","journal-title":"PLoS ONE"},{"issue":"2","key":"3040_CR77","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.brainresrev.2009.05.007","volume":"61","author":"T Nuutinen","year":"2009","unstructured":"Nuutinen T, Suuronen T, Kauppinen A, Salminen A (2009) Clusterin: a forgotten player in Alzheimer\u2019s disease. Brain Res Rev 61(2):89\u2013104. https:\/\/doi.org\/10.1016\/j.brainresrev.2009.05.007","journal-title":"Brain Res Rev"},{"issue":"11","key":"3040_CR78","doi-asserted-by":"publisher","first-page":"6875","DOI":"10.1074\/jbc.274.11.6875","volume":"274","author":"DT Humphreys","year":"1999","unstructured":"Humphreys DT, Carver JA, Easterbrook-Smith SB, Wilson MR (1999) Clusterin has chaperone-like activity similar to that of small heat shock proteins. J Biol Chem 274(11):6875\u20136881. https:\/\/doi.org\/10.1074\/jbc.274.11.6875","journal-title":"J Biol Chem"},{"issue":"22","key":"3040_CR79","doi-asserted-by":"publisher","first-page":"5380","DOI":"10.1021\/bi00474a025","volume":"29","author":"HV Silva De","year":"1990","unstructured":"De Silva HV, Harmony JAK, Stuart WD, Gil CM, Robbins J (1990) Apolipoprotein J: structure and tissue distribution. Biochemistry 29(22):5380\u20135389. https:\/\/doi.org\/10.1021\/bi00474a025","journal-title":"Biochemistry"},{"issue":"12","key":"3040_CR80","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1001\/archneurol.2010.201","volume":"67","author":"G Jun","year":"2010","unstructured":"Jun G, Naj AC, Beecham GW et al (2010) Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with apoe genotypes. Arch Neurol 67(12):1473\u20131484. https:\/\/doi.org\/10.1001\/archneurol.2010.201","journal-title":"Arch Neurol"},{"issue":"1","key":"3040_CR81","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1750-1326-7-3","volume":"7","author":"K Bettens","year":"2012","unstructured":"Bettens K, Brouwers N, Engelborghs S, Lambert J-C, Rogaeva E, Vandenberghe R, Le Bastard N, Pasquier F, Vermeulen S, Van Dongen J (2012) Both common variations and rare non-synonymous substitutions and small insertion\/deletions in CLU are associated with increased Alzheimer risk. Mol Neurodegener 7(1):3","journal-title":"Mol Neurodegener"},{"issue":"2","key":"3040_CR82","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/0006-8993(92)90071-G","volume":"579","author":"PL McGeer","year":"1992","unstructured":"McGeer PL, Kawamata T, Walker DG (1992) Distribution of clusterin in Alzheimer brain tissue. Brain Res 579(2):337\u2013341. https:\/\/doi.org\/10.1016\/0006-8993(92)90071-G","journal-title":"Brain Res"},{"issue":"Pt 2","key":"3040_CR83","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1042\/bj3160671","volume":"316","author":"E Matsubara","year":"1996","unstructured":"Matsubara E, Soto C, Governale S, Frangione B, Ghiso J (1996) Apolipoprotein J and Alzheimer\u2019s amyloid beta solubility. Biochem J 316(Pt 2):671\u2013679","journal-title":"Biochem J"},{"issue":"4","key":"3040_CR84","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/1097-0029(20000815)50:4<305::aid-jemt10>3.0.co;2-l","volume":"50","author":"M Calero","year":"2000","unstructured":"Calero M, Rostagno A, Matsubara E, Zlokovic B, Frangione B, Ghiso J (2000) Apolipoprotein J (clusterin) and Alzheimer\u2019s disease. Microsc Res Tech 50(4):305\u2013315. https:\/\/doi.org\/10.1002\/1097-0029(20000815)50:4%3c305:aid-jemt10%3e3.0.co;2-l","journal-title":"Microsc Res Tech"},{"issue":"5","key":"3040_CR85","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/sj.jcbfm.9600419","volume":"27","author":"RD Bell","year":"2007","unstructured":"Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, Zlokovic BV (2007) Transport pathways for clearance of human Alzheimer\u2019s amyloid \u03b2-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab 27(5):909\u2013918","journal-title":"J Cereb Blood Flow Metab"},{"issue":"1","key":"3040_CR86","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12868-018-0402-7","volume":"19","author":"X-M Qi","year":"2018","unstructured":"Qi X-M, Wang C, Chu X-K, Li G, Ma J-F (2018) Intraventricular infusion of clusterin ameliorated cognition and pathology in Tg6799 model of Alzheimer\u2019s disease. BMC Neurosci 19(1):2","journal-title":"BMC Neurosci"},{"issue":"11","key":"3040_CR87","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.2174\/1567205014666170531080948","volume":"14","author":"P Wang","year":"2017","unstructured":"Wang P, Chen K, Gu Y, Guo Q, Hong Z, Zhao Q (2017) \u03b2-Amyloid upregulates intracellular clusterin but not secretory clusterin in primary cultured neurons and APP mice. Curr Alzheimer Res 14(11):1207\u20131214. https:\/\/doi.org\/10.2174\/1567205014666170531080948","journal-title":"Curr Alzheimer Res"},{"issue":"2","key":"3040_CR88","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1006\/exnr.1998.6892","volume":"154","author":"AM Lidstr\u00f6m","year":"1998","unstructured":"Lidstr\u00f6m AM, Bogdanovic N, Hesse C, Volkman I, Davidsson P, Blennow K (1998) Clusterin (apolipoprotein J) protein levels are increased in hippocampus and in frontal cortex in Alzheimer\u2019s disease. Exp Neurol 154(2):511\u2013521. https:\/\/doi.org\/10.1006\/exnr.1998.6892","journal-title":"Exp Neurol"},{"key":"3040_CR89","doi-asserted-by":"publisher","unstructured":"Miners JS, Clarke P, Love S (2016) Clusterin levels are increased in Alzheimer\u2019s disease and influence the regional distribution of Abeta. Brain Pathol (Zurich, Switzerland). https:\/\/doi.org\/10.1111\/bpa.12392","DOI":"10.1111\/bpa.12392"},{"issue":"2","key":"3040_CR90","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0896-6273(03)00850-X","volume":"41","author":"RB DeMattos","year":"2004","unstructured":"DeMattos RB, Cirrito JR, Parsadanian M, May PC, O\u2019Dell MA, Taylor JW, Harmony JAK, Aronow BJ, Bales KR, Paul SM, Holtzman DM (2004) ApoE and clusterin cooperatively suppress A\u03b2 levels and deposition: evidence that ApoE regulates extracellular A\u03b2 metabolism in vivo. Neuron 41(2):193\u2013202. https:\/\/doi.org\/10.1016\/S0896-6273(03)00850-X","journal-title":"Neuron"},{"issue":"3","key":"3040_CR91","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1046\/j.1523-1747.1999.00531.x","volume":"112","author":"I Viard","year":"1999","unstructured":"Viard I, Wehrli P, Jornot L, Bullani R, Vechietti J-L, French LE, Schifferli JA, Tschopp J (1999) Clusterin gene expression mediates resistance to apoptotic cell death induced by heat shock and oxidative stress. J Investig Dermatol 112(3):290\u2013296. https:\/\/doi.org\/10.1046\/j.1523-1747.1999.00531.x","journal-title":"J Investig Dermatol"},{"issue":"5","key":"3040_CR92","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1083\/jcb.139.5.1281","volume":"139","author":"KG Wolter","year":"1997","unstructured":"Wolter KG, Hsu Y-T, Smith CL, Nechushtan A, Xi X-G, Youle RJ (1997) Movement of bax from the cytosol to mitochondria during apoptosis. J Cell Biol 139(5):1281\u20131292. https:\/\/doi.org\/10.1083\/jcb.139.5.1281","journal-title":"J Cell Biol"},{"key":"3040_CR93","doi-asserted-by":"publisher","unstructured":"Zhang H, Kim JK, Edwards CA, Xu Z, Taichman R, Wang C-Y (2005) Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol 7:909. https:\/\/doi.org\/10.1038\/ncb1291 . https:\/\/www.nature.com\/articles\/ncb1291#supplementary-information","DOI":"10.1038\/ncb1291"},{"issue":"5\u20137","key":"3040_CR94","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s10735-006-9052-7","volume":"37","author":"B Shannan","year":"2006","unstructured":"Shannan B, Seifert M, Boothman D, Tilgen W, Reichrath J (2006) Clusterin and DNA repair: a new function in cancer for a key player in apoptosis and cell cycle control. J Mol Histol 37(5\u20137):183\u2013188","journal-title":"J Mol Histol"},{"issue":"3","key":"3040_CR95","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1006\/mcne.1994.1027","volume":"5","author":"IH Zwain","year":"1994","unstructured":"Zwain IH, Grima J, Cheng CY (1994) Regulation of clusterin secretion and mRNA expression in astrocytes by cytokines. Mol Cell Neurosci 5(3):229\u2013237. https:\/\/doi.org\/10.1006\/mcne.1994.1027","journal-title":"Mol Cell Neurosci"},{"issue":"1\u20132","key":"3040_CR96","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/0014-5793(92)80330-J","volume":"297","author":"L Kirszbaum","year":"1992","unstructured":"Kirszbaum L, Bozas S, Walker I (1992) SP-40, 40, a protein involved in the control of the complement pathway, possesses a unique array of disulphide bridges. FEBS Lett 297(1\u20132):70\u201376","journal-title":"FEBS Lett"},{"key":"3040_CR97","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/B978-0-12-394317-0.00011-X","volume":"56","author":"Z-C Wu","year":"2012","unstructured":"Wu Z-C, Yu J-T, Li Y, Tan L (2012) Clusterin in Alzheimer\u2019s disease. Adv Clin Chem 56:155","journal-title":"Adv Clin Chem"},{"issue":"40","key":"3040_CR98","doi-asserted-by":"publisher","first-page":"38214","DOI":"10.1074\/jbc.C300252200","volume":"278","author":"G Santilli","year":"2003","unstructured":"Santilli G, Aronow BJ, Sala A (2003) Essential requirement of apolipoprotein J (clusterin) signaling for I\u03baB expression and regulation of NF-\u03baB activity. J Biol Chem 278(40):38214\u201338219","journal-title":"J Biol Chem"},{"key":"3040_CR99","doi-asserted-by":"publisher","first-page":"208.e201","DOI":"10.1016\/j.neurobiolaging.2015.09.009","volume":"37","author":"Y Deming","year":"2016","unstructured":"Deming Y, Xia J, Cai Y, Lord J, Holmans P, Bertelsen S, Holtzman D, Morris JC, Bales K, Pickering EH, Kauwe J, Goate A, Cruchaga C (2016) A potential endophenotype for Alzheimer\u2019s disease: cerebrospinal fluid clusterin. Neurobiol Aging 37:208.e201\u2013208.e209. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2015.09.009","journal-title":"Neurobiol Aging"},{"issue":"Pt 5","key":"3040_CR100","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1177\/0004563213503456","volume":"51","author":"W Jongbloed","year":"2014","unstructured":"Jongbloed W, Herrebout MA, Blankenstein MA, Veerhuis R (2014) Quantification of clusterin in paired cerebrospinal fluid and plasma samples. Ann Clin Biochem 51(Pt 5):557\u2013567. https:\/\/doi.org\/10.1177\/0004563213503456","journal-title":"Ann Clin Biochem"},{"issue":"8","key":"3040_CR101","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.neuint.2005.12.005","volume":"48","author":"AM Nilselid","year":"2006","unstructured":"Nilselid AM, Davidsson P, Nagga K, Andreasen N, Fredman P, Blennow K (2006) Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms. Neurochem Int 48(8):718\u2013728. https:\/\/doi.org\/10.1016\/j.neuint.2005.12.005","journal-title":"Neurochem Int"},{"issue":"2","key":"3040_CR102","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1001\/jamaneurol.2013.4560","volume":"71","author":"RS Desikan","year":"2014","unstructured":"Desikan RS, Thompson WK, Holland D, Hess CP, Brewer JB, Zetterberg H, Blennow K, Andreassen OA, McEvoy LK, Hyman BT, Dale AM (2014) The role of clusterin in amyloid-beta-associated neurodegeneration. JAMA Neurol 71(2):180\u2013187. https:\/\/doi.org\/10.1001\/jamaneurol.2013.4560","journal-title":"JAMA Neurol"},{"key":"3040_CR103","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jns.2015.12.023","volume":"361","author":"H Prikrylova Vranova","year":"2016","unstructured":"Prikrylova Vranova H, Henykova E, Mares J, Kaiserova M, Mensikova K, Vastik M, Hlustik P, Zapletalova J, Strnad M, Stejskal D, Kanovsky P (2016) Clusterin CSF levels in differential diagnosis of neurodegenerative disorders. J Neurol Sci 361:117\u2013121. https:\/\/doi.org\/10.1016\/j.jns.2015.12.023","journal-title":"J Neurol Sci"},{"issue":"7","key":"3040_CR104","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1007\/s11064-008-9588-x","volume":"33","author":"C Sihlbom","year":"2008","unstructured":"Sihlbom C, Davidsson P, Sjogren M, Wahlund LO, Nilsson CL (2008) Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer\u2019s disease patients and healthy individuals. Neurochem Res 33(7):1332\u20131340. https:\/\/doi.org\/10.1007\/s11064-008-9588-x","journal-title":"Neurochem Res"},{"issue":"2","key":"3040_CR105","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/ana.21038","volume":"61","author":"EJ Finehout","year":"2007","unstructured":"Finehout EJ, Franck Z, Choe LH, Relkin N, Lee KH (2007) Cerebrospinal fluid proteomic biomarkers for Alzheimer\u2019s disease. Ann Neurol 61(2):120\u2013129. https:\/\/doi.org\/10.1002\/ana.21038","journal-title":"Ann Neurol"},{"issue":"5","key":"3040_CR106","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3233\/JAD-2001-3501","volume":"3","author":"AM Lidstrom","year":"2001","unstructured":"Lidstrom AM, Hesse C, Rosengren L, Fredman P, Davidsson P, Blennow K (2001) Normal levels of clusterin in cerebrospinal fluid in Alzheimer\u2019s disease, and no change after acute ischemic stroke. J Alzheimer\u2019s Dis 3(5):435\u2013442","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"6","key":"3040_CR107","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/j.1742-4658.2010.07568.x","volume":"277","author":"M Sakono","year":"2010","unstructured":"Sakono M, Zako T (2010) Amyloid oligomers: formation and toxicity of Abeta oligomers. FEBS J 277(6):1348\u20131358. https:\/\/doi.org\/10.1111\/j.1742-4658.2010.07568.x","journal-title":"FEBS J"},{"issue":"4","key":"3040_CR108","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1523\/jneurosci.3501-06.2007","volume":"27","author":"PN Lacor","year":"2007","unstructured":"Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL, Klein WL (2007) Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer\u2019s disease. J Neurosci 27(4):796\u2013807. https:\/\/doi.org\/10.1523\/jneurosci.3501-06.2007","journal-title":"J Neurosci"},{"key":"3040_CR109","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/416535a","volume":"416","author":"DM Walsh","year":"2002","unstructured":"Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid \u03b2 protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:535. https:\/\/doi.org\/10.1038\/416535a","journal-title":"Nature"},{"issue":"8","key":"3040_CR110","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1523\/jneurosci.1675-13.2014","volume":"34","author":"MJ Savage","year":"2014","unstructured":"Savage MJ, Kalinina J, Wolfe A, Tugusheva K, Korn R, Cash-Mason T, Maxwell JW, Hatcher NG, Haugabook SJ, Wu G, Howell BJ, Renger JJ, Shughrue PJ, McCampbell A (2014) A sensitive abeta oligomer assay discriminates Alzheimer\u2019s and aged control cerebrospinal fluid. J Neurosci 34(8):2884\u20132897. https:\/\/doi.org\/10.1523\/jneurosci.1675-13.2014","journal-title":"J Neurosci"},{"issue":"4","key":"3040_CR111","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3233\/jad-2012-120211","volume":"31","author":"GM Sancesario","year":"2012","unstructured":"Sancesario GM, Cencioni MT, Esposito Z, Borsellino G, Nuccetelli M, Martorana A, Battistini L, Sorge R, Spalletta G, Ferrazzoli D, Bernardi G, Bernardini S, Sancesario G (2012) The load of amyloid-beta oligomers is decreased in the cerebrospinal fluid of Alzheimer\u2019s disease patients. J Alzheimer\u2019s Dis 31(4):865\u2013878. https:\/\/doi.org\/10.3233\/jad-2012-120211","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"1","key":"3040_CR112","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3233\/jad-2012-111361","volume":"29","author":"AN Santos","year":"2012","unstructured":"Santos AN, Ewers M, Minthon L, Simm A, Silber RE, Blennow K, Prvulovic D, Hansson O, Hampel H (2012) Amyloid-beta oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer\u2019s disease. J Alzheimer\u2019s Dis 29(1):171\u2013176. https:\/\/doi.org\/10.3233\/jad-2012-111361","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"1","key":"3040_CR113","first-page":"5","volume":"51","author":"MH Kazakova","year":"2009","unstructured":"Kazakova MH, Sarafian VS (2009) YKL-40\u2014a novel biomarker in clinical practice? Folia Med 51(1):5\u201314","journal-title":"Folia Med"},{"issue":"4","key":"3040_CR114","first-page":"351","volume":"110","author":"B Volck","year":"1998","unstructured":"Volck B, Price PA, Johansen JS, Sorensen O, Benfield TL, Nielsen HJ, Calafat J, Borregaard N (1998) YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Phys 110(4):351\u2013360","journal-title":"Proc Assoc Am Phys"},{"issue":"2","key":"3040_CR115","first-page":"172","volume":"53","author":"JS Johansen","year":"2006","unstructured":"Johansen JS (2006) Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 53(2):172\u2013209","journal-title":"Dan Med Bull"},{"issue":"5","key":"3040_CR116","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/jbmr.5650070506","volume":"7","author":"JS Johansen","year":"1992","unstructured":"Johansen JS, Williamson MK, Rice JS, Price PA (1992) Identification of proteins secreted by human osteoblastic cells in culture. J Bone Miner Res 7(5):501\u2013512. https:\/\/doi.org\/10.1002\/jbmr.5650070506","journal-title":"J Bone Miner Res"},{"issue":"1","key":"3040_CR117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1742-2094-7-34","volume":"7","author":"D Bonneh-Barkay","year":"2010","unstructured":"Bonneh-Barkay D, Wang G, Starkey A, Hamilton RL, Wiley CA (2010) In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases. J Neuroinflamm 7(1):1\u20138. https:\/\/doi.org\/10.1186\/1742-2094-7-34","journal-title":"J Neuroinflamm"},{"key":"3040_CR118","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1742-2094-3-27","volume":"3","author":"CA Colton","year":"2006","unstructured":"Colton CA, Mott RT, Sharpe H, Xu Q, Van Nostrand WE, Vitek MP (2006) Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. J Neuroinflamm 3:27. https:\/\/doi.org\/10.1186\/1742-2094-3-27","journal-title":"J Neuroinflamm"},{"key":"3040_CR119","doi-asserted-by":"publisher","first-page":"756357","DOI":"10.1100\/2012\/756357","volume":"2012","author":"JM Rubio-Perez","year":"2012","unstructured":"Rubio-Perez JM, Morillas-Ruiz JM (2012) A review: inflammatory process in Alzheimer\u2019s disease, role of cytokines. Sci World J 2012:756357. https:\/\/doi.org\/10.1100\/2012\/756357","journal-title":"Sci World J"},{"issue":"1","key":"3040_CR120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s004010050664","volume":"94","author":"JG Sheng","year":"1997","unstructured":"Sheng JG, Mrak RE, Griffin WS (1997) Neuritic plaque evolution in Alzheimer\u2019s disease is accompanied by transition of activated microglia from primed to enlarged to phagocytic forms. Acta Neuropathol 94(1):1\u20135","journal-title":"Acta Neuropathol"},{"key":"3040_CR121","doi-asserted-by":"publisher","unstructured":"Lee CY, Landreth GE (2010) The role of microglia in amyloid clearance from the AD brain. J Neural Transm (Vienna, Austria: 1996) 117(8):949\u2013960. https:\/\/doi.org\/10.1007\/s00702-010-0433-4","DOI":"10.1007\/s00702-010-0433-4"},{"issue":"46","key":"3040_CR122","doi-asserted-by":"publisher","first-page":"39904","DOI":"10.1074\/jbc.M111.267583","volume":"286","author":"U Neniskyte","year":"2011","unstructured":"Neniskyte U, Neher JJ, Brown GC (2011) Neuronal death induced by nanomolar amyloid beta is mediated by primary phagocytosis of neurons by microglia. J Biol Chem 286(46):39904\u201339913. https:\/\/doi.org\/10.1074\/jbc.M111.267583","journal-title":"J Biol Chem"},{"issue":"3","key":"3040_CR123","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.neurobiolaging.2004.05.010","volume":"26","author":"RE Mrak","year":"2005","unstructured":"Mrak RE, Griffin WS (2005) Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging 26(3):349\u2013354. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2004.05.010","journal-title":"Neurobiol Aging"},{"issue":"1","key":"3040_CR124","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/acn3.266","volume":"3","author":"S Janelidze","year":"2016","unstructured":"Janelidze S, Hertze J, Zetterberg H, Landqvist Waldo M, Santillo A, Blennow K, Hansson O (2016) Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer\u2019s disease. Ann Clin Transl Neurol 3(1):12\u201320. https:\/\/doi.org\/10.1002\/acn3.266","journal-title":"Ann Clin Transl Neurol"},{"issue":"8","key":"3040_CR125","doi-asserted-by":"publisher","first-page":"e0135458","DOI":"10.1371\/journal.pone.0135458","volume":"10","author":"M Wennstr\u00f6m","year":"2015","unstructured":"Wennstr\u00f6m M, Surova Y, Hall S, Nilsson C, Minthon L, Hansson O, Nielsen HM (2015) The inflammatory marker YKL-40 is elevated in cerebrospinal fluid from patients with Alzheimer\u2019s but not Parkinson\u2019s disease or dementia with Lewy bodies. PLoS ONE 10(8):e0135458. https:\/\/doi.org\/10.1371\/journal.pone.0135458","journal-title":"PLoS ONE"},{"issue":"3","key":"3040_CR126","doi-asserted-by":"publisher","first-page":"901","DOI":"10.3233\/JAD-140624","volume":"42","author":"A Antonell","year":"2014","unstructured":"Antonell A, Mansilla A, Rami L, Llad\u00f3 A, Iranzo A, Olives J, Balasa M, Sanchez-Valle R, Molinuevo JL (2014) Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer\u2019s disease. J Alzheimer\u2019s Dis 42(3):901\u2013908","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"9","key":"3040_CR127","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1001\/jamaneurol.2015.1285","volume":"72","author":"CL Sutphen","year":"2015","unstructured":"Sutphen CL, Jasielec MS, Shah AR et al (2015) Longitudinal cerebrospinal fluid biomarker changes in preclinical alzheimer disease during middle age. JAMA Neurol 72(9):1029\u20131042. https:\/\/doi.org\/10.1001\/jamaneurol.2015.1285","journal-title":"JAMA Neurol"},{"issue":"1","key":"3040_CR128","doi-asserted-by":"publisher","first-page":"e995","DOI":"10.1038\/tp.2016.252","volume":"7","author":"K Hoglund","year":"2017","unstructured":"Hoglund K, Kern S, Zettergren A, Borjesson-Hansson A, Zetterberg H, Skoog I, Blennow K (2017) Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration. Transl Psychiatry 7(1):e995. https:\/\/doi.org\/10.1038\/tp.2016.252","journal-title":"Transl Psychiatry"},{"key":"3040_CR129","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.dadm.2016.12.002","volume":"6","author":"JD Gispert","year":"2017","unstructured":"Gispert JD, Mont\u00e9 GC, Su\u00e1rez-Calvet M, Falcon C, Tucholka A, Rojas S, Rami L, S\u00e1nchez-Valle R, Llad\u00f3 A, Kleinberger G, Haass C, Molinuevo JL (2017) The APOE \u03b54 genotype modulates CSF YKL-40 levels and their structural brain correlates in the continuum of Alzheimer\u2019s disease but not those of sTREM2. Alzheimer\u2019s Dement Diagn Assess Dis Monit 6:50\u201359. https:\/\/doi.org\/10.1016\/j.dadm.2016.12.002","journal-title":"Alzheimer\u2019s Dement Diagn Assess Dis Monit"},{"key":"3040_CR130","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.neurobiolaging.2015.10.022","volume":"38","author":"JD Gispert","year":"2016","unstructured":"Gispert JD, Mont\u00e9 GC, Falcon C, Tucholka A, Rojas S, S\u00e1nchez-Valle R, Antonell A, Llad\u00f3 A, Rami L, Molinuevo JL (2016) CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD. Neurobiol Aging 38:47\u201355","journal-title":"Neurobiol Aging"},{"key":"3040_CR131","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13195-015-0161-y","volume":"7","author":"K Hellwig","year":"2015","unstructured":"Hellwig K, Kvartsberg H, Portelius E, Andreasson U, Oberstein TJ, Lewczuk P, Blennow K, Kornhuber J, Maler JM, Zetterberg H, Spitzer P (2015) Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer\u2019s disease. Alzheimer\u2019s Res Ther 7:74. https:\/\/doi.org\/10.1186\/s13195-015-0161-y","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"3040_CR132","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13195-015-0142-1","volume":"7","author":"MI Kester","year":"2015","unstructured":"Kester MI, Teunissen CE, Sutphen C, Herries EM, Ladenson JH, Xiong C, Scheltens P, van der Flier WM, Morris JC, Holtzman DM, Fagan AM (2015) Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer\u2019s disease in a memory clinic cohort. Alzheimer\u2019s Res Ther 7:59. https:\/\/doi.org\/10.1186\/s13195-015-0142-1","journal-title":"Alzheimer\u2019s Res Ther"},{"issue":"6","key":"3040_CR133","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/j.neurobiolaging.2015.03.001","volume":"36","author":"D Alcolea","year":"2015","unstructured":"Alcolea D, Vilaplana E, Pegueroles J, Montal V, S\u00e1nchez-Juan P, Gonz\u00e1lez-Su\u00e1rez A, Pozueta A, Rodr\u00edguez-Rodr\u00edguez E, Bartr\u00e9s-Faz D, Vidal-Pi\u00f1eiro D (2015) Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer\u2019s disease. Neurobiol Aging 36(6):2018\u20132023","journal-title":"Neurobiol Aging"},{"issue":"2","key":"3040_CR134","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/10454411950060020101","volume":"6","author":"DT Graves","year":"1995","unstructured":"Graves DT, Jiang Y (1995) Chemokines, a family of chemotactic cytokines. Crit Rev Oral Biol Med 6(2):109\u2013118","journal-title":"Crit Rev Oral Biol Med"},{"issue":"6","key":"3040_CR135","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMra052723","volume":"354","author":"IF Charo","year":"2006","unstructured":"Charo IF, Ransohoff RM (2006) The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354(6):610\u2013621. https:\/\/doi.org\/10.1056\/NEJMra052723","journal-title":"N Engl J Med"},{"issue":"5","key":"3040_CR136","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/j.1440-1827.1998.tb03915.x","volume":"48","author":"S Kato","year":"1998","unstructured":"Kato S, Gondo T, Hoshii Y, Takahashi M, Yamada M, Ishihara T (1998) Confocal observation of senile plaques in Alzheimer\u2019s disease: senile plaque morphology and relationship between senile plaques and astrocytes. Pathol Int 48(5):332\u2013340","journal-title":"Pathol Int"},{"key":"3040_CR137","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nm838","volume":"9","author":"T Wyss-Coray","year":"2003","unstructured":"Wyss-Coray T, Loike JD, Brionne TC, Lu E, Anankov R, Yan F, Silverstein SC, Husemann J (2003) Adult mouse astrocytes degrade amyloid-\u03b2 in vitro and in situ. Nat Med 9:453. https:\/\/doi.org\/10.1038\/nm838","journal-title":"Nat Med"},{"issue":"4","key":"3040_CR138","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/nm1555","volume":"13","author":"J Khoury El","year":"2007","unstructured":"El Khoury J, Toft M, Hickman SE, Means TK, Terada K, Geula C, Luster AD (2007) Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med 13(4):432\u2013438. https:\/\/doi.org\/10.1038\/nm1555","journal-title":"Nat Med"},{"issue":"4","key":"3040_CR139","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/j.1474-9728.2004.00101.x","volume":"3","author":"I Blasko","year":"2004","unstructured":"Blasko I, Stampfer-Kountchev M, Robatscher P, Veerhuis R, Eikelenboom P, Grubeck-Loebenstein B (2004) How chronic inflammation can affect the brain and support the development of Alzheimer\u2019s disease in old age: the role of microglia and astrocytes. Aging Cell 3(4):169\u2013176. https:\/\/doi.org\/10.1111\/j.1474-9728.2004.00101.x","journal-title":"Aging Cell"},{"issue":"10","key":"3040_CR140","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1006\/cyto.1997.0232","volume":"9","author":"G Forloni","year":"1997","unstructured":"Forloni G, Mangiarotti F, Angeretti N, Lucca E, De Simoni MG (1997) Beta-amyloid fragment potentiates IL-6 and TNF-alpha secretion by LPS in astrocytes but not in microglia. Cytokine 9(10):759\u2013762. https:\/\/doi.org\/10.1006\/cyto.1997.0232","journal-title":"Cytokine"},{"issue":"4","key":"3040_CR141","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nm838","volume":"9","author":"T Wyss-Coray","year":"2003","unstructured":"Wyss-Coray T, Loike JD, Brionne TC, Lu E, Anankov R, Yan F, Silverstein SC, Husemann J (2003) Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat Med 9(4):453\u2013457. https:\/\/doi.org\/10.1038\/nm838","journal-title":"Nat Med"},{"issue":"1","key":"3040_CR142","doi-asserted-by":"publisher","first-page":"e30525","DOI":"10.1371\/journal.pone.0030525","volume":"7","author":"K Westin","year":"2012","unstructured":"Westin K, Buchhave P, Nielsen H, Minthon L, Janciauskiene S, Hansson O (2012) CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer\u2019s disease. PLoS One 7(1):e30525. https:\/\/doi.org\/10.1371\/journal.pone.0030525","journal-title":"PLoS One"},{"issue":"4","key":"3040_CR143","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1001\/archneur.63.4.538","volume":"63","author":"D Galimberti","year":"2006","unstructured":"Galimberti D, Schoonenboom N, Scheltens P et al (2006) Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch Neurol 63(4):538\u2013543. https:\/\/doi.org\/10.1001\/archneur.63.4.538","journal-title":"Arch Neurol"},{"issue":"1","key":"3040_CR144","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000089137","volume":"21","author":"I Blasko","year":"2006","unstructured":"Blasko I, Lederer W, Oberbauer H, Walch T, Kemmler G, Hinterhuber H, Marksteiner J, Humpel C (2006) Measurement of thirteen biological markers in CSF of patients with Alzheimer\u2019s disease and other dementias. Dement Geriatr Cogn Disord 21(1):9\u201315. https:\/\/doi.org\/10.1159\/000089137","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"9","key":"3040_CR145","doi-asserted-by":"publisher","first-page":"e867","DOI":"10.1212\/wnl.0000000000006082","volume":"91","author":"S Janelidze","year":"2018","unstructured":"Janelidze S, Mattsson N, Stomrud E, Lindberg O, Palmqvist S, Zetterberg H, Blennow K, Hansson O (2018) CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology 91(9):e867\u2013e877. https:\/\/doi.org\/10.1212\/wnl.0000000000006082","journal-title":"Neurology"},{"issue":"2","key":"3040_CR146","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1159\/000362164","volume":"4","author":"C Ros\u00e9n","year":"2014","unstructured":"Ros\u00e9n C, Andersson CH, Andreasson U, Molinuevo JL, Bjerke M, Rami L, Llad\u00f3 A, Blennow K, Zetterberg H (2014) Increased levels of chitotriosidase and YKL-40 in cerebrospinal fluid from patients with Alzheimer\u2019s disease. Dement Geriatr Cogn Disord Extra 4(2):297\u2013304","journal-title":"Dement Geriatr Cogn Disord Extra"},{"issue":"3","key":"3040_CR147","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1590\/S0004-282X2011000400009","volume":"69","author":"JD Correa","year":"2011","unstructured":"Correa JD, Starling D, Teixeira AL, Caramelli P, Silva TA (2011) Chemokines in CSF of Alzheimer\u2019s disease patients. Arq Neuropsiquiatr 69(3):455\u2013459","journal-title":"Arq Neuropsiquiatr"},{"issue":"2","key":"3040_CR148","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3988\/jcn.2008.4.2.84","volume":"4","author":"C Choi","year":"2008","unstructured":"Choi C, Jeong JH, Jang JS, Choi K, Lee J, Kwon J, Choi KG, Lee JS, Kang SW (2008) Multiplex analysis of cytokines in the serum and cerebrospinal fluid of patients with Alzheimer\u2019s disease by color-coded bead technology. J Clin Neurol (Seoul, Korea) 4(2):84\u201388. https:\/\/doi.org\/10.3988\/jcn.2008.4.2.84","journal-title":"J Clin Neurol (Seoul, Korea)"},{"issue":"2","key":"3040_CR149","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/BF02740632","volume":"15","author":"DD Gerendasy","year":"1997","unstructured":"Gerendasy DD, Sutcliffe JG (1997) RC3\/neurogranin, a postsynaptic calpacitin for setting the response threshold to calcium influxes. Mol Neurobiol 15(2):131\u2013163","journal-title":"Mol Neurobiol"},{"issue":"19","key":"3040_CR150","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1038\/emboj.2009.273","volume":"28","author":"Y Hayashi","year":"2009","unstructured":"Hayashi Y (2009) Long-term potentiation: two pathways meet at neurogranin. EMBO J 28(19):2859\u20132860. https:\/\/doi.org\/10.1038\/emboj.2009.273","journal-title":"EMBO J"},{"issue":"5","key":"3040_CR151","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/ana.410270502","volume":"27","author":"ST DeKosky","year":"1990","unstructured":"DeKosky ST, Scheff SW (1990) Synapse loss in frontal cortex biopsies in Alzheimer\u2019s disease: correlation with cognitive severity. Ann Neurol 27(5):457\u2013464. https:\/\/doi.org\/10.1002\/ana.410270502","journal-title":"Ann Neurol"},{"issue":"3","key":"3040_CR152","first-page":"209","volume":"18","author":"C Bertoni-Freddari","year":"1996","unstructured":"Bertoni-Freddari C, Fattoretti P, Casoli T, Caselli U, Meier-Ruge W (1996) Deterioration threshold of synaptic morphology in aging and senile dementia of Alzheimer\u2019s type. Anal Quant Cytol Histol (The International Academy of Cytology and American Society of Cytology) 18(3):209\u2013213","journal-title":"Anal Quant Cytol Histol (The International Academy of Cytology and American Society of Cytology)"},{"issue":"18","key":"3040_CR153","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1212\/01.wnl.0000260698.46517.8f","volume":"68","author":"SW Scheff","year":"2007","unstructured":"Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ (2007) Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 68(18):1501\u20131508. https:\/\/doi.org\/10.1212\/01.wnl.0000260698.46517.8f","journal-title":"Neurology"},{"issue":"1","key":"3040_CR154","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/0304-3940(94)90121-X","volume":"174","author":"E Masliah","year":"1994","unstructured":"Masliah E, Mallory M, Hansen L, DeTeresa R, Alford M, Terry R (1994) Synaptic and neuritic alterations during the progression of Alzheimer\u2019s disease. Neurosci Lett 174(1):67\u201372","journal-title":"Neurosci Lett"},{"issue":"11","key":"3040_CR155","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nrneurol.2015.178","volume":"11","author":"I Fyfe","year":"2015","unstructured":"Fyfe I (2015) Alzheimer disease: neurogranin in the CSF signals early Alzheimer disease and predicts disease progression. Nat Rev Neurol 11(11):609. https:\/\/doi.org\/10.1038\/nrneurol.2015.178","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"3040_CR156","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1212\/WNL.56.1.127","volume":"56","author":"E Masliah","year":"2001","unstructured":"Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW Jr, Morris JC (2001) Altered expression of synaptic proteins occurs early during progression of Alzheimer\u2019s disease. Neurology 56(1):127\u2013129","journal-title":"Neurology"},{"issue":"2","key":"3040_CR157","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3233\/JAD-2005-7203","volume":"7","author":"PH Reddy","year":"2005","unstructured":"Reddy PH, Mani G, Park BS, Jacques J, Murdoch G, Whetsell W Jr, Kaye J, Manczak M (2005) Differential loss of synaptic proteins in Alzheimer\u2019s disease: implications for synaptic dysfunction. J Alzheimer\u2019s Dis 7(2):103\u2013117 (discussion 173\u2013180)","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"11","key":"3040_CR158","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1529\/biophysj.107.106849","volume":"93","author":"Y Kubota","year":"2007","unstructured":"Kubota Y, Putkey JA, Waxham MN (2007) Neurogranin controls the spatiotemporal pattern of postsynaptic Ca2+\/CaM signaling. Biophys J 93(11):3848\u20133859. https:\/\/doi.org\/10.1529\/biophysj.107.106849","journal-title":"Biophys J"},{"issue":"47","key":"3040_CR159","doi-asserted-by":"publisher","first-page":"10660","DOI":"10.1523\/JNEUROSCI.2213-04.2004","volume":"24","author":"K-P Huang","year":"2004","unstructured":"Huang K-P, Huang FL, J\u00e4ger T, Li J, Reymann KG, Balschun D (2004) Neurogranin\/RC3 enhances long-term potentiation and learning by promoting calcium-mediated signaling. J Neurosci 24(47):10660\u201310669","journal-title":"J Neurosci"},{"issue":"4","key":"3040_CR160","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1046\/j.1471-4159.2001.00646.x","volume":"79","author":"N Mons","year":"2001","unstructured":"Mons N, Enderlin V, Jaffard R, Higueret P (2001) Selective age-related changes in the PKC-sensitive, calmodulin-binding protein, neurogranin, in the mouse brain. J Neurochem 79(4):859\u2013867","journal-title":"J Neurochem"},{"issue":"11","key":"3040_CR161","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.jalz.2016.04.005","volume":"12","author":"E Bereczki","year":"2016","unstructured":"Bereczki E, Francis PT, Howlett D, Pereira JB, Hoglund K, Bogstedt A, Cedazo-Minguez A, Baek JH, Hortobagyi T, Attems J, Ballard C, Aarsland D (2016) Synaptic proteins predict cognitive decline in Alzheimer\u2019s disease and Lewy body dementia. Alzheimer\u2019s Dement 12(11):1149\u20131158. https:\/\/doi.org\/10.1016\/j.jalz.2016.04.005","journal-title":"Alzheimer\u2019s Dement"},{"issue":"Pt 11","key":"3040_CR162","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1093\/brain\/awv267","volume":"138","author":"E Portelius","year":"2015","unstructured":"Portelius E, Zetterberg H, Skillback T, Tornqvist U, Andreasson U, Trojanowski JQ, Weiner MW, Shaw LM, Mattsson N, Blennow K (2015) Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer\u2019s disease. Brain 138(Pt 11):3373\u20133385. https:\/\/doi.org\/10.1093\/brain\/awv267","journal-title":"Brain"},{"issue":"10","key":"3040_CR163","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.jalz.2014.10.009","volume":"11","author":"H Kvartsberg","year":"2015","unstructured":"Kvartsberg H, Duits FH, Ingelsson M, Andreasen N, Ohrfelt A, Andersson K, Brinkmalm G, Lannfelt L, Minthon L, Hansson O, Andreasson U, Teunissen CE, Scheltens P, Van der Flier WM, Zetterberg H, Portelius E, Blennow K (2015) Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer\u2019s disease. Alzheimer\u2019s Dement 11(10):1180\u20131190. https:\/\/doi.org\/10.1016\/j.jalz.2014.10.009","journal-title":"Alzheimer\u2019s Dement"},{"issue":"11","key":"3040_CR164","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1001\/jamaneurol.2015.1867","volume":"72","author":"MI Kester","year":"2015","unstructured":"Kester MI, Teunissen CE, Crimmins DL et al (2015) Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic Alzheimer disease. JAMA Neurol 72(11):1275\u20131280. https:\/\/doi.org\/10.1001\/jamaneurol.2015.1867","journal-title":"JAMA Neurol"},{"issue":"5","key":"3040_CR165","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/jamaneurol.2016.0086","volume":"73","author":"R Tarawneh","year":"2016","unstructured":"Tarawneh R, D\u2019Angelo G, Crimmins D, Herries E, Griest T, Fagan AM, Zipfel GJ, Ladenson JH, Morris JC, Holtzman DM (2016) Diagnostic and prognostic utility of the synaptic marker neurogranin in Alzheimer disease. JAMA Neurol 73(5):561\u2013571. https:\/\/doi.org\/10.1001\/jamaneurol.2016.0086","journal-title":"JAMA Neurol"},{"issue":"9","key":"3040_CR166","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1212\/wnl.0000000000002423","volume":"86","author":"H Wellington","year":"2016","unstructured":"Wellington H, Paterson RW, Portelius E, Tornqvist U, Magdalinou N, Fox NC, Blennow K, Schott JM, Zetterberg H (2016) Increased CSF neurogranin concentration is specific to Alzheimer disease. Neurology 86(9):829\u2013835. https:\/\/doi.org\/10.1212\/wnl.0000000000002423","journal-title":"Neurology"},{"issue":"3","key":"3040_CR167","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s00401-018-1851-x","volume":"136","author":"E Portelius","year":"2018","unstructured":"Portelius E, Olsson B, Hoglund K, Cullen NC, Kvartsberg H, Andreasson U, Zetterberg H, Sandelius A, Shaw LM, Lee VMY, Irwin DJ, Grossman M, Weintraub D, Chen-Plotkin A, Wolk DA, McCluskey L, Elman L, McBride J, Toledo JB, Trojanowski JQ, Blennow K (2018) Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. Acta Neuropathol 136(3):363\u2013376. https:\/\/doi.org\/10.1007\/s00401-018-1851-x","journal-title":"Acta Neuropathol"},{"issue":"10","key":"3040_CR168","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.15252\/emmm.201606540","volume":"8","author":"N Mattsson","year":"2016","unstructured":"Mattsson N, Insel PS, Palmqvist S, Portelius E, Zetterberg H, Weiner M, Blennow K, Hansson O (2016) Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer\u2019s disease. EMBO Mol Med 8(10):1184\u20131196. https:\/\/doi.org\/10.15252\/emmm.201606540","journal-title":"EMBO Mol Med"},{"key":"3040_CR169","doi-asserted-by":"publisher","unstructured":"Sanfilippo C, Forlenza O, Zetterberg H, Blennow K (2016) Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer\u2019s disease and in mild cognitive impairment due to AD. J Neural Transm (Vienna, Austria: 1996) 123(12):1443\u20131447. https:\/\/doi.org\/10.1007\/s00702-016-1597-3","DOI":"10.1007\/s00702-016-1597-3"},{"issue":"4","key":"3040_CR170","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.3233\/jad-160227","volume":"53","author":"A Vos De","year":"2016","unstructured":"De Vos A, Struyfs H, Jacobs D, Fransen E, Klewansky T, De Roeck E, Robberecht C, Van Broeckhoven C, Duyckaerts C, Engelborghs S, Vanmechelen E (2016) The cerebrospinal fluid neurogranin\/BACE1 ratio is a potential correlate of cognitive decline in Alzheimer\u2019s disease. J Alzheimer\u2019s Dis 53(4):1523\u20131538. https:\/\/doi.org\/10.3233\/jad-160227","journal-title":"J Alzheimer\u2019s Dis"},{"key":"3040_CR171","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.brainres.2010.09.073","volume":"1362","author":"A Thorsell","year":"2010","unstructured":"Thorsell A, Bjerke M, Gobom J, Brunhage E, Vanmechelen E, Andreasen N, Hansson O, Minthon L, Zetterberg H, Blennow K (2010) Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer\u2019s disease. Brain Res 1362:13\u201322. https:\/\/doi.org\/10.1016\/j.brainres.2010.09.073","journal-title":"Brain Res"},{"key":"3040_CR172","doi-asserted-by":"crossref","unstructured":"Bouchon A, Dietrich J, Colonna M (2000) Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol (Baltimore, MD: 1950) 164(10):4991\u20134995","DOI":"10.4049\/jimmunol.164.10.4991"},{"issue":"6","key":"3040_CR173","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nri1106","volume":"3","author":"M Colonna","year":"2003","unstructured":"Colonna M (2003) TREMs in the immune system and beyond. Nat Rev Immunol 3(6):445\u2013453. https:\/\/doi.org\/10.1038\/nri1106","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"3040_CR174","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1046\/j.1471-4159.2002.01243.x","volume":"83","author":"CD Schmid","year":"2002","unstructured":"Schmid CD, Sautkulis LN, Danielson PE, Cooper J, Hasel KW, Hilbush BS, Sutcliffe JG, Carson MJ (2002) Heterogeneous expression of the triggering receptor expressed on myeloid cells-2 on adult murine microglia. J Neurochem 83(6):1309\u20131320. https:\/\/doi.org\/10.1046\/j.1471-4159.2002.01243.x","journal-title":"J Neurochem"},{"issue":"4","key":"3040_CR175","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1111\/j.1471-4159.2009.06042.x","volume":"109","author":"CL Hsieh","year":"2009","unstructured":"Hsieh CL, Koike M, Spusta SC, Niemi EC, Yenari M, Nakamura MC, Seaman WE (2009) A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. J Neurochem 109(4):1144\u20131156. https:\/\/doi.org\/10.1111\/j.1471-4159.2009.06042.x","journal-title":"J Neurochem"},{"issue":"4","key":"3040_CR176","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1084\/jem.20041611","volume":"201","author":"K Takahashi","year":"2005","unstructured":"Takahashi K, Rochford CDP, Neumann H (2005) Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med 201(4):647\u2013657. https:\/\/doi.org\/10.1084\/jem.20041611","journal-title":"J Exp Med"},{"key":"3040_CR177","doi-asserted-by":"crossref","unstructured":"Hamerman JA, Jarjoura JR, Humphrey MB, Nakamura MC, Seaman WE, Lanier LL (2006) Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12. J Immunol (Baltimore, MD: 1950) 177(4):2051\u20132055","DOI":"10.4049\/jimmunol.177.4.2051"},{"issue":"13","key":"3040_CR178","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1002\/glia.20710","volume":"56","author":"S Frank","year":"2008","unstructured":"Frank S, Burbach GJ, Bonin M, Walter M, Streit W, Bechmann I, Deller T (2008) TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice. Glia 56(13):1438\u20131447. https:\/\/doi.org\/10.1002\/glia.20710","journal-title":"Glia"},{"issue":"2","key":"3040_CR179","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1211103","volume":"368","author":"T Jonsson","year":"2013","unstructured":"Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, Rujescu D, Hampel H, Giegling I, Andreassen OA, Engedal K, Ulstein I, Djurovic S, Ibrahim-Verbaas C, Hofman A, Ikram MA, van Duijn CM, Thorsteinsdottir U, Kong A, Stefansson K (2013) Variant of TREM2 associated with the risk of Alzheimer\u2019s disease. N Engl J Med 368(2):107\u2013116. https:\/\/doi.org\/10.1056\/NEJMoa1211103","journal-title":"N Engl J Med"},{"issue":"21","key":"3040_CR180","doi-asserted-by":"publisher","first-page":"5838","DOI":"10.1093\/hmg\/ddu277","volume":"23","author":"SC Jin","year":"2014","unstructured":"Jin SC, Benitez BA, Karch CM, Cooper B, Skorupa T, Carrell D, Norton JB, Hsu S, Harari O, Cai Y, Bertelsen S, Goate AM, Cruchaga C (2014) Coding variants in TREM2 increase risk for Alzheimer\u2019s disease. Hum Mol Genet 23(21):5838\u20135846. https:\/\/doi.org\/10.1093\/hmg\/ddu277","journal-title":"Hum Mol Genet"},{"issue":"2","key":"3040_CR181","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa1211851","volume":"368","author":"R Guerreiro","year":"2013","unstructured":"Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JSK, Younkin S, Hazrati L, Collinge J, Pocock J, Lashley T, Williams J, Lambert J-C, Amouyel P, Goate A, Rademakers R, Morgan K, Powell J, St. George-Hyslop P, Singleton A, Hardy J (2013) TREM2 variants in Alzheimer\u2019s disease. N Engl J Med 368(2):117\u2013127. https:\/\/doi.org\/10.1056\/NEJMoa1211851","journal-title":"N Engl J Med"},{"issue":"6","key":"3040_CR182","doi-asserted-by":"publisher","first-page":"602.e604","DOI":"10.1016\/j.jalz.2014.05.1751","volume":"10","author":"CF Slattery","year":"2014","unstructured":"Slattery CF, Beck JA, Harper L, Adamson G, Abdi Z, Uphill J, Campbell T, Druyeh R, Mahoney CJ, Rohrer JD, Kenny J, Lowe J, Leung KK, Barnes J, Clegg SL, Blair M, Nicholas JM, Guerreiro RJ, Rowe JB, Ponto C, Zerr I, Kretzschmar H, Gambetti P, Crutch SJ, Warren JD, Rossor MN, Fox NC, Collinge J, Schott JM, Mead S (2014) R47H TREM2 variant increases risk of typical early-onset Alzheimer\u2019s disease but not of prion or frontotemporal dementia. Alzheimer\u2019s Dement 10(6):602.e604\u2013608.e604. https:\/\/doi.org\/10.1016\/j.jalz.2014.05.1751","journal-title":"Alzheimer\u2019s Dement"},{"key":"3040_CR183","first-page":"10","volume":"1","author":"L Bertram","year":"2015","unstructured":"Bertram L (2015) The role of TREM2 R47H as a risk factor for Alzheimer\u2019s disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson\u2019s disease. Alzheimer\u2019s Dement 1:10","journal-title":"Alzheimer\u2019s Dement"},{"key":"3040_CR184","doi-asserted-by":"publisher","unstructured":"Kleinberger G, Yamanishi Y, Suarez-Calvet M, Czirr E, Lohmann E, Cuyvers E, Struyfs H, Pettkus N, Wenninger-Weinzierl A, Mazaheri F, Tahirovic S, Lleo A, Alcolea D, Fortea J, Willem M, Lammich S, Molinuevo JL, Sanchez-Valle R, Antonell A, Ramirez A, Heneka MT, Sleegers K, van der Zee J, Martin JJ, Engelborghs S, Demirtas-Tatlidede A, Zetterberg H, Van Broeckhoven C, Gurvit H, Wyss-Coray T, Hardy J, Colonna M, Haass C (2014) TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med 6(243):243ra286. https:\/\/doi.org\/10.1126\/scitranslmed.3009093","DOI":"10.1126\/scitranslmed.3009093"},{"issue":"4","key":"3040_CR185","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/nrn.2016.7","volume":"17","author":"M Colonna","year":"2016","unstructured":"Colonna M, Wang Y (2016) TREM2 variants: new keys to decipher Alzheimer disease pathogenesis. Nat Rev Neurosci 17(4):201\u2013207. https:\/\/doi.org\/10.1038\/nrn.2016.7","journal-title":"Nat Rev Neurosci"},{"issue":"Pt 11","key":"3040_CR186","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1093\/brain\/awn217","volume":"131","author":"L Piccio","year":"2008","unstructured":"Piccio L, Buonsanti C, Cella M, Tassi I, Schmidt RE, Fenoglio C, Rinker J 2nd, Naismith RT, Panina-Bordignon P, Passini N, Galimberti D, Scarpini E, Colonna M, Cross AH (2008) Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation. Brain 131(Pt 11):3081\u20133091. https:\/\/doi.org\/10.1093\/brain\/awn217","journal-title":"Brain"},{"issue":"6","key":"3040_CR187","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00401-016-1533-5","volume":"131","author":"L Piccio","year":"2016","unstructured":"Piccio L, Deming Y, Del-Aguila JL, Ghezzi L, Holtzman DM, Fagan AM, Fenoglio C, Galimberti D, Borroni B, Cruchaga C (2016) Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol 131(6):925\u2013933. https:\/\/doi.org\/10.1007\/s00401-016-1533-5","journal-title":"Acta Neuropathol"},{"issue":"3","key":"3040_CR188","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1084\/jem.20160844","volume":"214","author":"L Zhong","year":"2017","unstructured":"Zhong L, Chen X-F, Wang T, Wang Z, Liao C, Wang Z, Huang R, Wang D, Li X, Wu L (2017) Soluble TREM2 induces inflammatory responses and enhances microglial survival. J Exp Med 214(3):597\u2013607","journal-title":"J Exp Med"},{"issue":"6","key":"3040_CR189","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.cell.2015.01.049","volume":"160","author":"Y Wang","year":"2015","unstructured":"Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH, Holtzman DM, Cirrito JR, Colonna M (2015) TREM2 lipid sensing sustains the microglial response in an Alzheimer\u2019s disease model. Cell 160(6):1061\u20131071. https:\/\/doi.org\/10.1016\/j.cell.2015.01.049","journal-title":"Cell"},{"key":"3040_CR190","doi-asserted-by":"publisher","unstructured":"Suarez-Calvet M, Araque Caballero MA, Kleinberger G, Bateman RJ, Fagan AM, Morris JC, Levin J, Danek A, Ewers M, Haass C (2016) Early changes in CSF sTREM2 in dominantly inherited Alzheimer\u2019s disease occur after amyloid deposition and neuronal injury. Sci Transl Med 8(369):369ra178. https:\/\/doi.org\/10.1126\/scitranslmed.aag1767","DOI":"10.1126\/scitranslmed.aag1767"},{"issue":"5","key":"3040_CR191","doi-asserted-by":"publisher","first-page":"437","DOI":"10.15252\/emmm.201606245","volume":"8","author":"SE Schindler","year":"2016","unstructured":"Schindler SE, Holtzman DM (2016) CSF sTREM2: marking the tipping point between preclinical AD and dementia? EMBO Mol Med 8(5):437\u2013438. https:\/\/doi.org\/10.15252\/emmm.201606245","journal-title":"EMBO Mol Med"},{"issue":"12","key":"3040_CR192","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.jalz.2016.06.005","volume":"12","author":"JD Gispert","year":"2016","unstructured":"Gispert JD, Suarez-Calvet M, Monte GC, Tucholka A, Falcon C, Rojas S, Rami L, Sanchez-Valle R, Llado A, Kleinberger G, Haass C, Molinuevo JL (2016) Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer\u2019s disease. Alzheimer\u2019s Dement 12(12):1259\u20131272. https:\/\/doi.org\/10.1016\/j.jalz.2016.06.005","journal-title":"Alzheimer\u2019s Dement"},{"key":"3040_CR193","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13024-016-0071-x","volume":"11","author":"A Heslegrave","year":"2016","unstructured":"Heslegrave A, Heywood W, Paterson R, Magdalinou N, Svensson J, Johansson P, Ohrfelt A, Blennow K, Hardy J, Schott J, Mills K, Zetterberg H (2016) Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer\u2019s disease. Mol Neurodegener 11:3. https:\/\/doi.org\/10.1186\/s13024-016-0071-x","journal-title":"Mol Neurodegener"},{"issue":"5","key":"3040_CR194","doi-asserted-by":"publisher","first-page":"466","DOI":"10.15252\/emmm.201506123","volume":"8","author":"M Suarez-Calvet","year":"2016","unstructured":"Suarez-Calvet M, Kleinberger G, Araque Caballero MA, Brendel M, Rominger A, Alcolea D, Fortea J, Lleo A, Blesa R, Gispert JD, Sanchez-Valle R, Antonell A, Rami L, Molinuevo JL, Brosseron F, Traschutz A, Heneka MT, Struyfs H, Engelborghs S, Sleegers K, Van Broeckhoven C, Zetterberg H, Nellgard B, Blennow K, Crispin A, Ewers M, Haass C (2016) sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer\u2019s disease and associate with neuronal injury markers. EMBO Mol Med 8(5):466\u2013476. https:\/\/doi.org\/10.15252\/emmm.201506123","journal-title":"EMBO Mol Med"},{"issue":"1","key":"3040_CR195","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13195-016-0182-1","volume":"8","author":"K Henjum","year":"2016","unstructured":"Henjum K, Almdahl IS, Arskog V, Minthon L, Hansson O, Fladby T, Nilsson LN (2016) Cerebrospinal fluid soluble TREM2 in aging and Alzheimer\u2019s disease. Alzheimer\u2019s Res Ther 8(1):17. https:\/\/doi.org\/10.1186\/s13195-016-0182-1","journal-title":"Alzheimer\u2019s Res Ther"},{"issue":"6","key":"3040_CR196","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/BF02911388","volume":"10","author":"K Yoshimoto","year":"1995","unstructured":"Yoshimoto K, Tanaka T, Somiya K, Tsuji R, Okamoto F, Kawamura K, Ohkaru Y, Asayama K, Ishii H (1995) Human heart-type cytoplasmic fatty acid-binding protein as an indicator of acute myocardial infarction. Heart Vessels 10(6):304\u2013309","journal-title":"Heart Vessels"},{"key":"3040_CR197","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.plipres.2013.10.002","volume":"53","author":"CI Janssen","year":"2014","unstructured":"Janssen CI, Kiliaan AJ (2014) Long-chain polyunsaturated fatty acids (LCPUFA) from genesis to senescence: the influence of LCPUFA on neural development, aging, and neurodegeneration. Prog Lipid Res 53:1\u201317. https:\/\/doi.org\/10.1016\/j.plipres.2013.10.002","journal-title":"Prog Lipid Res"},{"key":"3040_CR198","doi-asserted-by":"publisher","unstructured":"Veerkamp JH, Zimmerman AW (2001) Fatty acid-binding proteins of nervous tissue. J Mol Neurosci 16(2\u20133):133\u2013142. https:\/\/doi.org\/10.1385\/jmn:16:2-3:133 (discussion 151\u2013137)","DOI":"10.1385\/jmn:16:2-3:133"},{"issue":"3","key":"3040_CR199","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.nbd.2008.12.002","volume":"33","author":"CR Hooijmans","year":"2009","unstructured":"Hooijmans CR, Van der Zee CEEM, Dederen PJ, Brouwer KM, Reijmer YD, van Groen T, Broersen LM, L\u00fctjohann D, Heerschap A, Kiliaan AJ (2009) DHA and cholesterol containing diets influence Alzheimer-like pathology, cognition and cerebral vasculature in APPswe\/PS1dE9 mice. Neurobiol Dis 33(3):482\u2013498. https:\/\/doi.org\/10.1016\/j.nbd.2008.12.002","journal-title":"Neurobiol Dis"},{"issue":"5","key":"3040_CR200","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1007\/s12035-015-9224-0","volume":"53","author":"Y Tan","year":"2016","unstructured":"Tan Y, Ren H, Shi Z, Yao X, He C, Kang J-X, Wan J-B, Li P, Yuan T-F, Su H (2016) Endogenous docosahexaenoic acid (DHA) prevents A\u03b21\u201342 oligomer-induced neuronal injury. Mol Neurobiol 53(5):3146\u20133153. https:\/\/doi.org\/10.1007\/s12035-015-9224-0","journal-title":"Mol Neurobiol"},{"key":"3040_CR201","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/978-3-7091-6721-2_20","volume":"67","author":"MS Cheon","year":"2003","unstructured":"Cheon MS, Kim SH, Fountoulakis M, Lubec G (2003) Heart type fatty acid binding protein (H-FABP) is decreased in brains of patients with Down syndrome and Alzheimer\u2019s disease. J Neural Transm Suppl 67:225\u2013234","journal-title":"J Neural Transm Suppl"},{"issue":"1","key":"3040_CR202","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cccn.2004.09.001","volume":"352","author":"MMAL Pelsers","year":"2005","unstructured":"Pelsers MMAL, Hermens WT, Glatz JFC (2005) Fatty acid-binding proteins as plasma markers of tissue injury. Clin Chim Acta 352(1):15\u201335. https:\/\/doi.org\/10.1016\/j.cccn.2004.09.001","journal-title":"Clin Chim Acta"},{"key":"3040_CR203","doi-asserted-by":"publisher","unstructured":"Glatz JFC (1998) Fatty acid-binding protein as a plasma marker for the early detection of myocardial injury. In: Kaski JC, Holt DW (eds) Myocardial damage: early detection by novel biochemical markers. Springer Netherlands, Dordrecht, pp 73\u201384. https:\/\/doi.org\/10.1007\/978-94-017-2380-0_7","DOI":"10.1007\/978-94-017-2380-0_7"},{"issue":"8","key":"3040_CR204","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1523\/JNEUROSCI.4140-09.2010","volume":"30","author":"N Shioda","year":"2010","unstructured":"Shioda N, Yamamoto Y, Watanabe M, Binas B, Owada Y, Fukunaga K (2010) Heart-type fatty acid binding protein regulates dopamine D2 receptor function in mouse brain. J Neurosci 30(8):3146\u20133155","journal-title":"J Neurosci"},{"issue":"27","key":"3040_CR205","doi-asserted-by":"publisher","first-page":"18957","DOI":"10.1074\/jbc.M113.527341","volume":"289","author":"N Shioda","year":"2014","unstructured":"Shioda N, Yabuki Y, Kobayashi Y, Onozato M, Owada Y, Fukunaga K (2014) FABP3 protein promotes \u03b1-synuclein oligomerization associated with 1-methyl-1, 2, 3, 6-tetrahydropiridine-induced neurotoxicity. J Biol Chem 289(27):18957\u201318965","journal-title":"J Biol Chem"},{"key":"3040_CR206","doi-asserted-by":"publisher","unstructured":"Martorana A, Koch G (2014) Is dopamine involved in Alzheimer\u2019s disease? Front Aging Neurosci. https:\/\/doi.org\/10.3389\/fnagi.2014.00252","DOI":"10.3389\/fnagi.2014.00252"},{"key":"3040_CR207","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1750-1326-8-39","volume":"8","author":"RS Desikan","year":"2013","unstructured":"Desikan RS, Thompson WK, Holland D, Hess CP, Brewer JB, Zetterberg H, Blennow K, Andreassen OA, McEvoy LK, Hyman BT, Dale AM (2013) Heart fatty acid binding protein and Abeta-associated Alzheimer\u2019s neurodegeneration. Mol Neurodegener 8:39. https:\/\/doi.org\/10.1186\/1750-1326-8-39","journal-title":"Mol Neurodegener"},{"issue":"7","key":"3040_CR208","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s00406-013-0405-4","volume":"263","author":"LH Guo","year":"2013","unstructured":"Guo LH, Alexopoulos P, Perneczky R (2013) Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer\u2019s disease. Eur Arch Psychiatry Clin Neurosci 263(7):553\u2013560. https:\/\/doi.org\/10.1007\/s00406-013-0405-4","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"4","key":"3040_CR209","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.3233\/jad-2010-101293","volume":"22","author":"D Chiasserini","year":"2010","unstructured":"Chiasserini D, Parnetti L, Andreasson U, Zetterberg H, Giannandrea D, Calabresi P, Blennow K (2010) CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer\u2019s disease. J Alzheimer\u2019s Dis 22(4):1281\u20131288. https:\/\/doi.org\/10.3233\/jad-2010-101293","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"3","key":"3040_CR210","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3233\/jad-150525","volume":"49","author":"M Bjerke","year":"2016","unstructured":"Bjerke M, Kern S, Blennow K, Zetterberg H, Waern M, Borjesson-Hanson A, Ostling S, Kern J, Skoog I (2016) Cerebrospinal fluid fatty acid-binding protein 3 is related to dementia development in a population-based sample of older adult women followed for 8 years. J Alzheimer\u2019s Dis 49(3):733\u2013741. https:\/\/doi.org\/10.3233\/jad-150525","journal-title":"J Alzheimer\u2019s Dis"},{"key":"3040_CR211","doi-asserted-by":"crossref","unstructured":"Biscetti L, Eusebi P, Salvadori N, Frattini G, Simoni S, Mollenhauer B, Engelborghs S, Tambasco N, Calabresi P, Parnetti L, Chiasserini D (2016) Combination of cerebrospinal fluid h-fabp and core Alzheimer\u2019s Disease biomarkers improves the differential diagnosis of neurodegenerative disorders. Alzheimer\u2019s Dement 12(7 suppl):P201\u2013P202. http:\/\/dx.doi.org\/10.1016\/j.jalz.2016.06.353","DOI":"10.1016\/j.jalz.2016.06.353"},{"issue":"Suppl 2","key":"3040_CR212","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1016\/j.parkreldis.2015.10.037","volume":"22","author":"D Chiasserini","year":"2016","unstructured":"Chiasserini D, Biscetti L, Eusebi P, Farotti L, Tambasco N, Calabresi P, Parnetti L (2016) CSF levels of heart fatty acid binding protein in Parkinson\u2019s and Alzheimer\u2019s disease. Parkinsonism Relat Disord 22(Suppl 2):e33. https:\/\/doi.org\/10.1016\/j.parkreldis.2015.10.037","journal-title":"Parkinsonism Relat Disord"},{"issue":"14","key":"3040_CR213","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1242\/jcs.104729","volume":"125","author":"A Yuan","year":"2012","unstructured":"Yuan A, Rao MV, Veeranna Nixon RA (2012) Neurofilaments at a glance. J Cell Sci 125(14):3257\u20133263. https:\/\/doi.org\/10.1242\/jcs.104729","journal-title":"J Cell Sci"},{"issue":"4","key":"3040_CR214","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/cm.20184","volume":"64","author":"Y Yan","year":"2007","unstructured":"Yan Y, Jensen K, Brown A (2007) The polypeptide composition of moving and stationary neurofilaments in cultured sympathetic neurons. Cell Motil Cytoskelet 64(4):299","journal-title":"Cell Motil Cytoskelet"},{"issue":"10","key":"3040_CR215","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1016\/j.yexcr.2007.04.025","volume":"313","author":"OI Wagner","year":"2007","unstructured":"Wagner OI, Rammensee S, Korde N, Wen Q, Leterrier J-F, Janmey PA (2007) Softness, strength and self-repair in intermediate filament networks. Exp Cell Res 313(10):2228\u20132235","journal-title":"Exp Cell Res"},{"issue":"10","key":"3040_CR216","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1016\/j.neurobiolaging.2015.07.003","volume":"36","author":"CM Fernandez-Martos","year":"2015","unstructured":"Fernandez-Martos CM, King AE, Atkinson RAK, Woodhouse A, Vickers JC (2015) Neurofilament light gene deletion exacerbates amyloid, dystrophic neurite, and synaptic pathology in the APP\/PS1 transgenic model of Alzheimer\u2019s disease. Neurobiol Aging 36(10):2757\u20132767. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2015.07.003","journal-title":"Neurobiol Aging"},{"issue":"3","key":"3040_CR217","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/jnr.1242","volume":"66","author":"M Sj\u00f6gren","year":"2001","unstructured":"Sj\u00f6gren M, Blomberg M, Jonsson M, Wahlund LO, Edman \u00c5, Lind K, Rosengren L, Blennow K, Wallin A (2001) Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J Neurosci Res 66(3):510\u2013516. https:\/\/doi.org\/10.1002\/jnr.1242","journal-title":"J Neurosci Res"},{"issue":"21","key":"3040_CR218","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1212\/wnl.0000000000001015","volume":"83","author":"T Skillback","year":"2014","unstructured":"Skillback T, Farahmand B, Bartlett JW, Rosen C, Mattsson N, Nagga K, Kilander L, Religa D, Wimo A, Winblad B, Rosengren L, Schott JM, Blennow K, Eriksdotter M, Zetterberg H (2014) CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology 83(21):1945\u20131953. https:\/\/doi.org\/10.1212\/wnl.0000000000001015","journal-title":"Neurology"},{"key":"3040_CR219","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.neurobiolaging.2016.09.012","volume":"49","author":"AV Idland","year":"2017","unstructured":"Idland AV, Sala-Llonch R, Borza T, Watne LO, Wyller TB, Braekhus A, Zetterberg H, Blennow K, Walhovd KB, Fjell AM (2017) CSF neurofilament light levels predict hippocampal atrophy in cognitively healthy older adults. Neurobiol Aging 49:138\u2013144. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2016.09.012","journal-title":"Neurobiol Aging"},{"issue":"1","key":"3040_CR220","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jamaneurol.2015.3037","volume":"73","author":"H Zetterberg","year":"2016","unstructured":"Zetterberg H, Skillb\u00e4ck T, Mattsson N et al (2016) Association of cerebrospinal fluid neurofilament light concentration with alzheimer disease progression. JAMA Neurol 73(1):60\u201367. https:\/\/doi.org\/10.1001\/jamaneurol.2015.3037","journal-title":"JAMA Neurol"},{"issue":"9","key":"3040_CR221","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1136\/jnnp.2006.107326","volume":"78","author":"D Jong De","year":"2007","unstructured":"De Jong D, Jansen RWMM, Pijnenburg YAL, van Geel WJA, Borm GF, Kremer HPH, Verbeek MM (2007) CSF neurofilament proteins in the differential diagnosis of dementia. J Neurol Neurosurg Psychiatry 78(9):936\u2013938. https:\/\/doi.org\/10.1136\/jnnp.2006.107326","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"3040_CR222","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/ana.24052","volume":"75","author":"CS Scherling","year":"2014","unstructured":"Scherling CS, Hall T, Berisha F, Klepac K, Karydas A, Coppola G, Kramer JH, Rabinovici G, Ahlijanian M, Miller BL, Seeley W, Grinberg LT, Rosen H, Meredith J Jr, Boxer AL (2014) Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol 75(1):116\u2013126. https:\/\/doi.org\/10.1002\/ana.24052","journal-title":"Ann Neurol"},{"issue":"5","key":"3040_CR223","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1212\/wnl.52.5.1090","volume":"52","author":"LE Rosengren","year":"1999","unstructured":"Rosengren LE, Karlsson J-E, Sj\u00f6gren M, Blennow K, Wallin A (1999) Neurofilament protein levels in CSF are increased in dementia. Neurology 52(5):1090. https:\/\/doi.org\/10.1212\/wnl.52.5.1090","journal-title":"Neurology"},{"issue":"1","key":"3040_CR224","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/bj3530001","volume":"353","author":"RD Burgoyne","year":"2001","unstructured":"Burgoyne RD, Weiss JL (2001) The neuronal calcium sensor family of Ca2+-binding proteins. Biochem J 353(1):1\u201312","journal-title":"Biochem J"},{"issue":"1","key":"3040_CR225","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3233\/jad-150060","volume":"47","author":"M Groblewska","year":"2015","unstructured":"Groblewska M, Muszynski P, Wojtulewska-Supron A, Kulczynska-Przybik A, Mroczko B (2015) The role of visinin-like protein-1 in the pathophysiology of Alzheimer\u2019s disease. J Alzheimer\u2019s Dis 47(1):17\u201332. https:\/\/doi.org\/10.3233\/jad-150060","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"8","key":"3040_CR226","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1023\/a:1007056731551","volume":"28","author":"H-G Bernstein","year":"1999","unstructured":"Bernstein H-G, Baumann B, Danos P, Diekmann S, Bogerts B, Gundelfinger ED, Braunewell K-H (1999) Regional and cellular distribution of neural visinin-like protein immunoreactivities (VILIP-1 and VILIP-3) in human brain. J Neurocytol 28(8):655\u2013662. https:\/\/doi.org\/10.1023\/a:1007056731551","journal-title":"J Neurocytol"},{"issue":"17","key":"3040_CR227","doi-asserted-by":"publisher","first-page":"7331","DOI":"10.1523\/JNEUROSCI.22-17-07331.2002","volume":"22","author":"C Spilker","year":"2002","unstructured":"Spilker C, Dresbach T, Braunewell KH (2002) Reversible translocation and activity-dependent localization of the calcium-myristoyl switch protein VILIP-1 to different membrane compartments in living hippocampal neurons. J Neurosci 22(17):7331\u20137339","journal-title":"J Neurosci"},{"issue":"1\u20132","key":"3040_CR228","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/S1570-9639(02)00452-1","volume":"1600","author":"C Spilker","year":"2002","unstructured":"Spilker C, Gundelfinger ED, Braunewell KH (2002) Evidence for different functional properties of the neuronal calcium sensor proteins VILIP-1 and VILIP-3: from subcellular localization to cellular function. Biochim Biophys Acta 1600(1\u20132):118\u2013127","journal-title":"Biochim Biophys Acta"},{"key":"3040_CR229","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1750-1326-4-20","volume":"4","author":"P Marambaud","year":"2009","unstructured":"Marambaud P, Dreses-Werringloer U, Vingtdeux V (2009) Calcium signaling in neurodegeneration. Mol Neurodegener 4:20. https:\/\/doi.org\/10.1186\/1750-1326-4-20","journal-title":"Mol Neurodegener"},{"issue":"22","key":"3040_CR230","doi-asserted-by":"publisher","first-page":"10573","DOI":"10.1073\/pnas.90.22.10573","volume":"90","author":"N Arispe","year":"1993","unstructured":"Arispe N, Pollard HB, Rojas E (1993) Giant multilevel cation channels formed by Alzheimer disease amyloid beta-protein [A beta P-(1-40)] in bilayer membranes. Proc Natl Acad Sci USA 90(22):10573\u201310577","journal-title":"Proc Natl Acad Sci USA"},{"key":"3040_CR231","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fnmol.2012.00020","volume":"5","author":"KH Braunewell","year":"2012","unstructured":"Braunewell KH (2012) The visinin-like proteins VILIP-1 and VILIP-3 in Alzheimer\u2019s disease-old wine in new bottles. Front Mol Neurosci 5:20. https:\/\/doi.org\/10.3389\/fnmol.2012.00020","journal-title":"Front Mol Neurosci"},{"issue":"2","key":"3040_CR232","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1159\/000051244","volume":"12","author":"K Braunewell","year":"2001","unstructured":"Braunewell K, Riederer P, Spilker C, Gundelfinger ED, Bogerts B, Bernstein HG (2001) Abnormal localization of two neuronal calcium sensor proteins, visinin-like proteins (vilips)-1 and -3, in neocortical brain areas of Alzheimer disease patients. Dement Geriatr Cogn Disord 12(2):110\u2013116","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"9","key":"3040_CR233","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1001\/archneur.58.9.1395","volume":"58","author":"JL Price","year":"2001","unstructured":"Price JL, Ko AI, Wade MJ, Tsou SK, McKeel DW, Morris JC (2001) Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol 58(9):1395\u20131402","journal-title":"Arch Neurol"},{"issue":"14","key":"3040_CR234","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1523\/JNEUROSCI.16-14-04491.1996","volume":"16","author":"T Gomez-Isla","year":"1996","unstructured":"Gomez-Isla T, Price JL, McKeel DW Jr, Morris JC, Growdon JH, Hyman BT (1996) Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer\u2019s disease. J Neurosci 16(14):4491\u20134500","journal-title":"J Neurosci"},{"key":"3040_CR235","doi-asserted-by":"publisher","unstructured":"Kirkwood CM, MacDonald ML, Schempf TA, Vatsavayi AV, Ikonomovic MD, Koppel JL, Ding Y, Sun M, Kofler JK, Lopez OL, Yates NA, Sweet RA (2016) Altered levels of Visinin-like protein 1 correspond to regional neuronal loss in Alzheimer disease and frontotemporal lobar degeneration. J Neuropathol Exp Neurol. https:\/\/doi.org\/10.1093\/jnen\/nlv018","DOI":"10.1093\/jnen\/nlv018"},{"issue":"5","key":"3040_CR236","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1006\/nbdi.2001.0432","volume":"8","author":"I Schnurra","year":"2001","unstructured":"Schnurra I, Bernstein HG, Riederer P, Braunewell KH (2001) The neuronal calcium sensor protein VILIP-1 is associated with amyloid plaques and extracellular tangles in Alzheimer\u2019s disease and promotes cell death and tau phosphorylation in vitro: a link between calcium sensors and Alzheimer\u2019s disease? Neurobiol Dis 8(5):900\u2013909. https:\/\/doi.org\/10.1006\/nbdi.2001.0432","journal-title":"Neurobiol Dis"},{"issue":"10","key":"3040_CR237","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1373\/clinchem.2008.104497","volume":"54","author":"JM Lee","year":"2008","unstructured":"Lee JM, Blennow K, Andreasen N, Laterza O, Modur V, Olander J, Gao F, Ohlendorf M, Ladenson JH (2008) The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. Clin Chem 54(10):1617\u20131623. https:\/\/doi.org\/10.1373\/clinchem.2008.104497","journal-title":"Clin Chem"},{"issue":"3","key":"3040_CR238","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3233\/jad-150705","volume":"50","author":"M Babic Leko","year":"2016","unstructured":"Babic Leko M, Borovecki F, Dejanovic N, Hof PR, Simic G (2016) Predictive value of cerebrospinal fluid Visinin-like protein-1 levels for Alzheimer\u2019s disease early detection and differential diagnosis in patients with mild cognitive impairment. J Alzheimer\u2019s Dis 50(3):765\u2013778. https:\/\/doi.org\/10.3233\/jad-150705","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"5","key":"3040_CR239","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/jnc.12331","volume":"127","author":"X Luo","year":"2013","unstructured":"Luo X, Hou L, Shi H, Zhong X, Zhang Y, Zheng D, Tan Y, Hu G, Mu N, Chan J, Chen X, Fang Y, Wu F, He H, Ning Y (2013) CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer\u2019s disease and dementia with Lewy bodies. J Neurochem 127(5):681\u2013690. https:\/\/doi.org\/10.1111\/jnc.12331","journal-title":"J Neurochem"},{"issue":"3","key":"3040_CR240","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.3233\/jad-141050","volume":"43","author":"B Mroczko","year":"2015","unstructured":"Mroczko B, Groblewska M, Zboch M, Muszynski P, Zajkowska A, Borawska R, Szmitkowski M, Kornhuber J, Lewczuk P (2015) Evaluation of visinin-like protein 1 concentrations in the cerebrospinal fluid of patients with mild cognitive impairment as a dynamic biomarker of Alzheimer\u2019s disease. J Alzheimer\u2019s Dis 43(3):1031\u20131037. https:\/\/doi.org\/10.3233\/jad-141050","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"2","key":"3040_CR241","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/ana.22448","volume":"70","author":"R Tarawneh","year":"2011","unstructured":"Tarawneh R, D\u2019Angelo G, Macy E, Xiong C, Carter D, Cairns NJ, Fagan AM, Head D, Mintun MA, Ladenson JH, Lee JM, Morris JC, Holtzman DM (2011) Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Ann Neurol 70(2):274\u2013285. https:\/\/doi.org\/10.1002\/ana.22448","journal-title":"Ann Neurol"},{"issue":"6","key":"3040_CR242","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1001\/jamaneurol.2015.0202","volume":"72","author":"R Tarawneh","year":"2015","unstructured":"Tarawneh R, Head D, Allison S, Buckles V, Fagan AM, Ladenson JH, Morris JC, Holtzman DM (2015) Cerebrospinal fluid markers of neurodegeneration and rates of brain atrophy in early Alzheimer disease. JAMA Neurol 72(6):656\u2013665. https:\/\/doi.org\/10.1001\/jamaneurol.2015.0202","journal-title":"JAMA Neurol"},{"issue":"10","key":"3040_CR243","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1212\/WNL.0b013e318248e568","volume":"78","author":"R Tarawneh","year":"2012","unstructured":"Tarawneh R, Lee JM, Ladenson JH, Morris JC, Holtzman DM (2012) CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. Neurology 78(10):709\u2013719. https:\/\/doi.org\/10.1212\/WNL.0b013e318248e568","journal-title":"Neurology"},{"issue":"3","key":"3040_CR244","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3233\/jad-150897","volume":"50","author":"KE Melah","year":"2016","unstructured":"Melah KE, Lu SY, Hoscheidt SM, Alexander AL, Adluru N, Destiche DJ, Carlsson CM, Zetterberg H, Blennow K, Okonkwo OC, Gleason CE, Dowling NM, Bratzke LC, Rowley HA, Sager MA, Asthana S, Johnson SC, Bendlin BB (2016) Cerebrospinal fluid markers of Alzheimer\u2019s disease pathology and microglial activation are associated with altered white matter microstructure in asymptomatic adults at risk for Alzheimer\u2019s disease. J Alzheimer\u2019s Dis 50(3):873\u2013886. https:\/\/doi.org\/10.3233\/jad-150897","journal-title":"J Alzheimer\u2019s Dis"},{"key":"3040_CR245","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.neuroscience.2015.05.018","volume":"300","author":"GZ R\u00e9us","year":"2015","unstructured":"R\u00e9us GZ, Fries GR, Stertz L, Badawy M, Passos IC, Barichello T, Kapczinski F, Quevedo J (2015) The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. Neuroscience 300:141\u2013154. https:\/\/doi.org\/10.1016\/j.neuroscience.2015.05.018","journal-title":"Neuroscience"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00018-019-03040-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-019-03040-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-019-03040-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T23:09:17Z","timestamp":1662937757000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00018-019-03040-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,15]]},"references-count":245,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["3040"],"URL":"https:\/\/doi.org\/10.1007\/s00018-019-03040-5","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,15]]},"assertion":[{"value":"28 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"KB has served as a consultant or at advisory boards for Alzheon, BioArctic, Biogen, Eli Lilly, Fujirebio Europe, IBL International, Merck, Novartis, Pfizer, and Roche Diagnostics, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. HZ has served at scientific advisory boards of Eli Lilly, Roche Diagnostics, Samumed, CogRx and Wave, has received travel support from Teva and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}